Identification and Characterization of MicroRNAs Involved in Parkinson’s Disease: Potential Role as Diagnostic Biomarkers. by Serafin, Alice
Alma Mater Studiorum – Università di Bologna 
 
 
DOTTORATO DI RICERCA IN 
 
SCIENZE MEDICHE SPECIALISTICHE 
 
Ciclo XXVIII 
 
 
 
Settore Concorsuale di afferenza: NEUROLOGIA 06/D6 
Settore Scientifico disciplinare: NEUROLOGIA MED/26 
 
 
 
Identification and Characterization of MicroRNAs Involved in 
Parkinson’s Disease: Potential Role as Diagnostic Biomarkers. 
 
 
 
 
 
 
Presentata da: Dott.ssa Alice Serafin 
 
 
 
Coordinatore Dottorato                     Relatore 
Prof. Roberto Di Bartolomeo   Prof. Pietro Cortelli  
 
 
 
 
 
 
Esame finale anno 2016 
 
Acknowledgments 
 
I would like to thank Prof. Pietro Cortelli, my PhD Tutor, who has always supported 
me, encouraged with energy and advised in giving the best, and guided me along 
my educational and professional way. 
 
 I would like to thank Dot. Christine Schwienbacher, Senior Researcher at Center 
of Biomedicine EURAC (The European Academy of Bolzano), who has followed 
my laboratory work with confidence, dedication and scientific curiosity and urged 
me to independence and to have a researcher's vision. 
 
I would also thank Luisa Foco, Anne Picard and Alessandra Zanon. 
 
 ABSTRACT ……………………………………………………………………………..…. 
 
1. INTRODUCTION .................................................................................................. 
1.1. Parkinsn’disease ………………………………………………………………….. 
1.2. MicroRNAs …………………………………………………………………………. 
1.2.1. MicroRNAs structure, biogenesis and mechanism of action……………. 
1.3. MicroRNAs and Parkinson’s disease …………………………………………….. 
1.3.1. MiRNAs as regulators of PD genes ……………………………………….. 
1.3.2. MicroRNAs as potential biomarker for Parkinson’s disease ……………. 
1.4. Common miRNAs normalization procedures in blood ………………………….. 
 
2. OBJECTIVE ……………………………………………………………………………… 
 
3. MATERIAL AND METHODS ………………………………………………………….. 
3.1. Standard protocol approvals, registrations, and patients consensus ............... 
3.2. RNA isolation and quality control …………………………………………………. 
3.3. Reverse Transcription and quantitative real time PCR ……………………….... 
3.4. Standard curve efficiency …………………………………………………….……. 
3.5. qRT-PCR normalization and relative quantification of miRNAs ………………. 
3.6. Statistical Analysis …………………………………………………….……………. 
3.7. Bioinformatic analysis: target prediction and priorization ………………………. 
3.8. Library preparation for NGS analysis …………………………………….…...….. 
3.9. Bioinformatic analysis workflow of the NGS data output ……………………..... 
 
4. RESULTS ………………………………………………………………………………… 
4.1. Identification of a reliable set of endogenous reference genes for PBMCs 
miRNAs expression studies in Parkinson disease’s ………………………….... 
4.2. Different combinations of reference genes set have a strong impact on the 
relative expression levels observed for both miR-29a-3p and miR-30b-5p ….. 
4.3. First evidence of miR-103a-3p over-expression and deregulation of miR-29a-
i 
 
1 
1 
4 
4 
8 
9 
10 
12 
 
14 
 
15 
15 
17 
18 
19 
20 
21 
23 
24 
25 
 
26 
 
26 
 
27 
 
3p and miR-30b-5p in PBMCs samples from L-dopa treated PD patients …... 
4.4. Trend of miR-30a-5p over-expression in plasma samples from L-dopa treated 
PD patients …………………………………….……………………………..…….. 
4.5. Confirmation of the exploratory data obtained in the 31 plasma samples from 
L-dopa treated PD patients in an enlarged sample size ………………………… 
4.6. Different miRNA expression profiles between PBMCs and plasma samples 
from L-dopa treated PD patients ………………………………………..………… 
4.7. Expression analysis on PBMCs and plasma samples from drug-naïve PD 
patients and unaffected matched controls ………………………….………….... 
4.7.1. MiRNAs expression analysis in PBMCs samples from drug-naїve PD 
patients and unaffected matched controls …………………..….…………... 
4.7.2. MiRNAs expression analysis in plasma samples from drug-naїve PD 
patients and unaffected matched controls ………………………………….. 
4.8. Preliminary statistical analysis suggested miRNAs over-expression trend 
according to the gender ………………………………………..………………...… 
4.9. Exploratory deep sequencing analysis on PBMCs samples from L-dopa 
treated PD patients and unaffected matched controls ………………………….. 
4.10. Sophisticated in silico approach predicts reliable and promising putative 
target genes ……………………………….………………………...………………. 
 
5. DISCUSSION ………………………………………………………………...………….. 
5.1. Importance of the miRNAs expression data normalization approach …………. 
5.2. Over-expression of miR-29a-3p and miR-30b-5p in PBMC samples from L-
dopa treated PD patients …………………………………………………………… 
5.3. Target prediction priorization ............................................................................ 
5.3.1. Bcl-2 as putative common target for all up-regulated miRNAs in PBMCs 
and plasma samples from L-dopa treated PD patients .............................. 
5.3.2. Insulin resistance and over-expression of miR-103a-3p ……………..…. 
5.4. The difference in miRNAs expression could be the consequence of L-dopa 
treatment rather than to the PD pathogenesis per se?  ................................... 
5.5. Plasma and blood as sources for PD biomarker .............................................. 
5.6. Deep sequencing analysis: new insight ........................................................... 
29 
 
31 
 
32 
 
33 
 
35 
 
35 
 
36 
 
37 
 
37 
 
40 
 
46 
46 
 
49 
50 
 
50 
53 
 
56 
57 
60 
 6. CONCLUSION …………………………………………………………………………… 
 
7. PERSPECTIVES ………………………………………………………………………… 
 
REFERENCES …………………………………………...………………………………….. 
 
 
63 
 
65 
 
67 
 
i 
 
Abstract
 
ABSTRACT 
 
Background. MicroRNAs (miRNAs) are small non-coding RNAs of 20-22 
nucleotides, involved in transcriptional and post-transcriptional regulation of gene 
expression. MiRNAs function via base-pairing with complementary sequences 
within target mRNA molecules, usually resulting in gene silencing via translational 
repression or target degradation. Research on miRNAs is becoming an 
increasingly attractive field, as these small RNA molecules are involved in several 
physiological functions and diseases. To date, only few studies have assessed the 
expression of peripheral blood mononuclear cells (PBMCs) and plasma miRNAs 
related to Parkinson’s disease (PD) using microarray and quantitative real-time 
polymerase chain reaction.  
Objective. The aim of the present study is to profile the expression of miR-29a-3p, 
miR-29b-3p, miR-30a-5p, miR-30b-5p, and miR-103a-3p and assess their 
potential role as biomarker for Parkinson’s disease. In order to define their 
potential as biomarker, we planned our study according to the following points (i) 
identification of a suitable set of commonly used small RNAs as normalizers to be 
considered reliable reference genes in qRT-PCR expression analyses on PBMCs 
samples from Levodopa (L-dopa) treated PD patients and disease-free matched 
controls and evaluate the consequence in expression’s direction of the target 
miRNAs (miR-29a-3p and miR-30b-5p) using different combinations of reference 
gene set; (ii) evaluation of the expression levels of miR-29a-3p, miR-29b-3p, miR-
30a-5p, miR-30b-5p, and miR-103a-3p first in PBMCs and then in plasma samples 
from L-dopa treated PD patients and disease-free matched controls; subsequent 
comparison of their expression profiles in order to assess whether the observed 
difference in miRNAs expression is present in both of them, and verify if plasma is 
a suitable alternative/additional easy accessible resource for PD miRNA 
biomarker; (iii) verify if the observed difference in miRNAs expression could be the 
consequence of treatment rather than the PD pathogenesis per se, performing an 
expression analysis on PBMCs and plasma samples from drug-naïve PD patients 
and disease-free matched controls; (iv) perform an exploratory deep sequencing 
analysis on 4 PBMCs samples from L-dopa treated PD patients and disease-free 
matched controls using Illumina MiSeq Next Generation Sequencing platform in  
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order to discover new miRNAs; (v) interpretation of the miRNAs expression data in 
a biological context through a more sophisticated in silico target prediction. 
Methods. Plasma and PBMCs miRNAs coming from L-dopa treated PD patients, 
drug-naïve PD patients, and unaffected controls matched 1:1 by sex and age, 
were analyzed. The expression analysis for miR-29a-3p, miR-29b-3p, miR-30a-5p, 
miR-30b-5p, and miR-103a-3p was performed by qRT-PCR and the data 
normalized using RNU24 and Z30 for PBMCs samples and the C.elegans 
synthetic oligos spike-in cel-miR-39-3p, cel-miR-54-3p and cel-miR-238-3p 
regarding plasma samples. The statistical significance of miRNA expression 
differences was calculated by computing a two-tailed paired t-test. NGS analysis 
was done using MiSeq Illumina platform. To detect putative miRNA targets, 
several miRNA resources were combined to generate an overall score for each 
candidate gene using weighted rank aggregation. 
Results. RNU24 and Z30 have been identified as reliable and stable set of 
reference genes to be use as normalizers for expression analysis in PBMCs 
samples from L-dopa treated PD and drug-naїve PD patients. The effect on the 
relative expression values of miR-29a-3p and miR-30b-5p has been tested using 
different combinations of reference genes. The normalization of the microRNAs 
expression using different reference gene sets results in a modification or in an 
opposite direction of the miRNAs expression. 
We revealed for the first time an over-expression of miR-103a-3p (p<0.0001) in 36 
PBMCs samples from L-dopa treated PD patients and matched controls. 
Moreover, we found an up-regulation of miR-29a-3p (p=0.005) and miR-30b-5p 
(p=0.002). The analysis on 31 plasma samples from L-dopa treated PD patients 
indicated a trend of over-expression of miR-30a-5p (p=0.054), whereas the miR-
29b-3p previously found expressed in peripheral blood samples could not be 
analyzed in plasma due to its extremely low expression level. The trend over-
expression of miR-30a-5p was confirmed in an independent secondary experiment 
on 50 plasma samples from L-dopa treated PD patients and controls matched 1:1 
by sex and age. Thus, indicating different miRNA expression profiles between 
PBMCs and plasma. 
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No differences in miRNAs expression levels in 10 PBMCs samples from drug-
naïve PD patients were found, whereas a borderline significant over-expression of 
miR-30b-5p (p=0.0858) was detected in 10 plasma samples from drug-naïve PD 
patients, thus indicating a potential involvement of the L-dopa treatment in the 
miRNAs expression. 
The very preliminary result of the subgroup analysis in plasma and blood, 
stratifying the samples by gender, suggests that there is a trend of differentially 
miRNA expression according to the gender. 
It has been defined the method for the library preparation for NGS analysis. Albeit 
the number of reads generated and the number of samples sequenced in this pilot 
phase, the data were not sufficient to generate sequencing results in a meaningful 
biological analysis.  
A sophisticated approach has been elaborated to obtain a promising in silico target 
prediction model, identifying interesting candidate target genes, including genes 
related to neurodegeneration and PD. 
Discussion. miRNAs expressed in peripheral blood and plasma are promising 
candidate diagnostic biomarkers due to the easy accessibility of the blood tissue. 
Our study shows for the first time an over-expression of miR-103a-3p in L-dopa 
treated PD patients and replicates a documented deregulation in PD, albeit 
opposite to published data, of miR-29a-3p and miR-30b-5p. Although the 
exploratory expression analysis performed on plasma samples from 10 drug-naïve 
PD patients and matched controls, showed a trend of higher expression of miR-
30b-5p, suggesting an involvement of the L-dopa treatment in the miRNA 
expression, no difference in expression levels of miRNAs was revealed in PBMCs 
samples from drug-naïve PD patients, deriving from the same individuals analyzed 
in plasma samples. So, further expression studies in a larger sample size should 
be performed to elucidate the putative role of L-dopa in the deregulation of the 
investigated miRNAs, in patients before and after drug administration.  
The in silico analysis identified putative candidate target genes, including genes 
related to neurodegeneration and PD, such as LRRK2 for miR-30b-5p and miR-
103a-3p, PARK7/DJ-1 for miR-29a-3p, Bcl-2 as common target for all miRNAs  
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(miR-30b-5p, miR-29a-3p, miR-103a-3p, and miR-30a-5p), or the involvement of 
miR-103a-3p in the insulin resistance. 
Despite the preliminary character of the study, the results provide a rationale for 
further clarifying the role of the identified miRNAs in the pathogenesis of PD, for 
validating their diagnostic potential, and future use as biomarkers to monitor or 
prevent the motors symptoms induced by L-dopa treatment. 
 
The obtained results have been published in two differents manuscripts, the first in 
Neurology (Serafin et al., “Overexpression of blood microRNAs 103a, 30b, and 
29a in L-dopa-treated patients with PD.”, 2015) and the second in BMC Research 
Notes (Serafin et al., “Identification of a set of endogenous reference genes for 
miRNA expression studies in Parkinson's disease blood samples.”, 2014) and a 
third one is under elaboration. 
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1. INTRODUCTION 
 
The aim of the present study is to profile the expression of miR-29a-3p, miR-29b-
3p, miR-30a-5p, miR-30b-5p, and miR-103a-3p and assess their potential role as 
diagnostic and/or prognostic biomarkers for Parkinson’s disease (PD). The study 
was conducted on peripheral blood mononuclear cells (PBMCs) and plasma 
samples from Levodopa (L-dopa) treated PD patients, drug-naïve PD patients and 
not affected controls matched 1:1 by sex and age. 
The subsequent chapter will give an introduction on Parkinson’s disease, 
microRNAs and their possible role in the pathogenesis of idiopathic Parkinson’s 
disease and their potential role in early diagnosis and disease progression. 
 
1.1 Parkinson’s disease 
 
Parkinson's disease is the second most common neurodegenerative disorder after 
Alzheimer’s disease. PD affects 1% of population beyond 65 years of age with 
high prevalence in men. Although approximately 10% of cases affect people under 
age 40, PD is primarily a disease of the elderly, only a small percentage of PD 
patients, mostly with the genetic forms of PD, develop parkinsonism before the 
age of 45. PD is the most frequent form of parkinsonism, a term used to describe 
movement disorders with parkinsonian features independent of their etiology. 
Parkinson’s disease is a progressive neurodegenerative disease, which is 
generally considered a multi-factorial disorder that arises due to a combination of 
genes and environmental factors. Most cases are idiopathic or late-onset PD (> 
85% of all cases), and a monogenic cause can be detected in about 2–3 % of the 
patients (Klein and Schlossmacher, 2007). Since our study only focuses on 
idiopathic PD, genetic forms of PD will not be described here. 
The majority of PD cases are sporadic, about 10-15% of patients report a positive 
family history. Although familial and idiopathic forms of the disease differ in several 
clinical aspects, it is clear that common molecular pathways underlie the 
neurodegeneration. These include oxidative stress, mitochondrial dysfunction, 
energy production imbalance and disruption of the ubiquitin-proteasome system.  
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The study of these pathways gives us some information about the mechanisms 
underlying PD, but the causative factors for idiopathic PD remain still unknown. 
PD is characterized clinically by restring tremor, rigidity, reduced motor activity 
(bradykinesia), and postural instability (Hoehn and Yahr, 1967), and pathologically 
by loss of dopaminergic neurons in the substantia nigra pars compacta and the 
presence of alfa-synuclein positive inclusions in the cytoplasm of neurons, termed 
Lewy bodies (Forno et al., 1996; Goedert et al., 2013; Spillantini et al., 1998b). 
The fundamental components of these inclusions are alfa-synuclein, neurofilament 
proteins, and ubiquitin (Forno et al., 1996). Although the majority of idiopathic PD 
has Lewy body pathology at autopsy, this feature is neither exclusive to this 
disease nor common to all cases (Halliday et al., 2011). Motor impairment is often 
associated to non-motor features such as autonomic, cognitive, and psychiatric 
problems, sensory loss and sleep disturbance, which are difficult to treat and often 
manifest before motor disability (Langston et al., 2006). Moreover, these motor 
dysfunctions become apparent when 70–80% of nigrostriatal nerve terminals have 
undergone degeneration, implicating a compensatory mechanism in the first 
stages of the disease (Bernheimer et al., 1973). Mild cognitive impairment and 
subsequent dementia is also common (Litvan et al., 2012).  
 
To date, there is no treatment to arrest or retard the progression of 
neurodegeneration. In fact, dopamine (DA) therapy can improve motor symptoms, 
but does not influence the rate of clinical disease progression and has serious side 
effects such as motor fluctuations and dyskinesias, due to the fluctuation in L-dopa 
concentration (Fahn, 2000,Schapira, 2007). Since DA administered orally is not 
able to cross the blood brain barrier, current therapy is based on administration of 
the dopamine precursor, named L-dopa. L-dopa crosses the blood-brain barrier 
and replaces the lack of dopamine in the striatum after conversion in dopamine, 
increasing the DA content in the brain. L-dopa is the most effective drug that acts 
on the symptoms of PD but it has a short period of half-life. In fact, the main issue 
related to L-dopa treatment is represented by its low bioavailability in the central 
nervous system, due to the rapid peripheral decarboxylation to dopamine 
(Colamartino et al., 2012). For that reason, it is necessary to combine the  
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treatment with drugs which inhibit the amino acid decarboxylase (AADC) such as 
Carbidopa, which increases the L-dopa half-life in central nervous system (CNS). 
Many patients with the progression of disease severity require higher doses of L-
dopa, causing motor complications. Because of the side effects in L-dopa 
treatment it would be important to be able to monitor its levels in blood, so that an 
individual personalized therapy could be developed, and could be possible predict 
and avoid significant motor fluctuations. Indeed, each patient requires a different 
dosage of drug and the use of miRNAs as biomarker could represent an important 
variable for therapy improvement. 
 
In the absence of reliable diagnostic markers, the clinical diagnosis of PD is based 
on the presence of characteristic features. Several diagnostic criteria have been 
developed for PD and in 1999 Gelb and colleagues proposed a set of diagnostic 
criteria for PD, based on a review of the literature regarding the sensitivity and 
specificity of the characteristic clinical features (Gelb et al, 1999). The reliability of 
the different diagnostic criteria, however, has not been vigorously tested by 
autopsy examination, that is commonly considered the gold standard. Two 
separate clinical-pathologic studies concluded that only 76% of the patients with a 
clinical diagnosis of PD actually met the pathologic criteria; the remaining 24% had 
evidence of other causes of parkinsonism. The clinical diagnosis of PD is mainly 
based on physical examination findings, from moderate to high accuracy 
(sensitivity and specificity of 88% and 95.4% respectively, with a positive 
predictive value of 85.7%). Much of the difficulty in the diagnosis of PD is in 
differentiating it from other disorders that cause parkinsonism. Moreover, 
predicting which patients with PD will have a relatively benign versus a more 
severe course of disease, such as the development of dementia, is also very 
difficult based solely on clinical grounds.  
Neuroimaging techniques have acquired an important role in the last decade. For 
example conventional magnetic resonance imaging (MRI) and advanced MRI 
techniques such as magnetic resonance spectroscopy (MRS), diffusion-weighted 
and diffusion tensor imaging and functional MRI, seems to be promising methods  
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in differential diagnosis of early PD with initial motor symptoms from atypical 
parkinsonian disorders, thus, making easier early diagnosis. Thus, the 
development of new potential therapeutics or predictable biomarkers for PD is 
essential for patient care. 
 
1.2 MicroRNAs 
 
Small RNAs are a variety of non-coding RNAs classes of 20-30 nucleotides long. 
Each class of small RNA differs in its origin and biogenesis, the proteins they 
interact with, the mechanism of action of the RNPs (RNA-protein complexes), and 
the nature of their targets.  
MiRNAs act as endogenous post-transcriptional regulators of gene expression by 
base-pairing with their target, the RNA messenger (mRNA). The AGO proteins 
play a role as effectors recruiting factors, that cause translational repression, 
mRNA deadenylation, and mRNA decay (Huntzinger, 2011). The miRNA-binding 
site is situated normally at the 3’ untranslated region (UTR) of mRNAs. MiRNA 
genes represent one of the most abundant gene families. To date, they have been 
annotated into a database called miRBase, 2588 human miRNAs and the miRNA 
number is constantly increasing (www.mirbase.org). 
 
1.2.1 MicroRNAs structure, biogenesis and mechanism of action 
 
The so-called miRNA-seed region represents the domain at the 5’end of the 
miRNA, which is extended from nucleotide position 2 to 7, and plays a key role in 
the target recognition. In human more than 60% of the genes coding for proteins 
contain at least one conserved miRNA binding-site, and considering the fact that 
also numerous not conserved sites exist, most protein-coding genes may be under 
the control of miRNA (Ha and Kim, 2014). The function of the miRNAs is tightly 
regulated, and their participation in the regulation of physiological cellular 
processes such as development and differentiation pathways, proliferation, stress 
response, metabolism and apoptosis has been demonstrated, also their  
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deregulation is often associated with human diseases such as cancer, 
autoimmune diseases and some nervous system disorders. 
 
Here below will be described the canonical biogenesis pathway of miRNAs (Ha 
and Kim, 2014; Winter et al., 2009; Wilfred et al., 2007). MiRNA genes are 
generally transcribed by RNA polymerase II producing a double-strand stem loop 
structure primary transcript, called pri-miRNA (over 1kb) characterized by a local 
hairpin structure. Tanscription factors, such as p53, MYC, MYOD (myoblast 
determination protein 1), and ZEB1 and ZEB2 associated to the RNA-Pol-II 
determine the positive or negative expression of miRNAs (Ha and Kim, 2014). 
Only pri-miRNA, which contains an appropriate stem, a large flexible terminal loop 
and the capability of producing a single stranded RNA overhangs at the 5’ and 3’ 
sides, will be efficiently processed and mature into functional miRNA. The stem-
loop sequence of the pri-miRNA is recognized by a series of enzymes that 
orchestrate a tightly controlled maturation process (Ha and Kim, 2014). The pri-
miRNA is processed by Drosha and cofactor DGCR8 (double-stranded RNA-
binding protein) called Pasha. Drosha is a nuclear protein of 160kDa, belonging to 
the family of the RNase III-type endonucleases, that acts specifically on double-
stranded RNA (dsRNA). The nuclear RNase Drosha together with cofactor 
DGCR8, initiate the maturation of the pri-miRNA, cutting the pri-miRNA stem loop 
in order to release a small hairpin-shaped RNA of ~60-70 nucleotides long, called 
pre-miRNA.  
Pre-miRNA is exported to the cytoplasm in order to complete its maturation. The 
translocation through the nuclear pore is regulated by protein exportin 5 (EXP5), 
which binds Ran-GTP and pre-miRNA forming a transport complex. The hydrolysis 
of GTP results in the disassembly of the complex and the release of the pre-
miRNA into the cytosol. The pre-miRNA transport through the nuclear membrane 
is specific due to the characteristic of EXP5 which recognizes a dsRNA stem of 
>14bp long that presents a short 3’ overhang (that is 1-8 nucleotides in length) (Ha 
and Kim, 2014). 
In the cytoplasm, a second RNase III enzyme of ~200kDa called Dicer, its cofactor  
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TRBP (transactivation response RNA-binding protein), and PACT (protein 
activator of PKR) mediate the conversion of pre-miRNA to mature miRNA, by 
cleaving the pre-miRNA near to the terminal loop, in an ATP-independent manner, 
generating a double-stranded miRNA duplex (miRNA:miRNA*) of ~22 nucleotides 
long consisting of the most abundant mature miRNA and the less abundant anti-
sense strand miRNA* (also called passenger strand). Each strand of the miRNA 
complex originates from opposite arms of the stem-loop. The miRNA duplex is 
loaded into Argonaute 1-4 proteins (Ago 1-4) complex as a double-strand RNA, 
forming a pre-RISC complex (RNA-induced silencing complex). This step is ATP-
dependent and requires the Hsc70/Hsp90 chaperone machinery (Kawamata et al., 
2011). Normally the second filament is degraded (miRNA*). However there are 
many cases in which also the second filament becomes a mature miRNA and 
plays an active role in the regulation of the target mRNA. The pre-RISC complex 
(in which the Ago protein associate with the miRNA duplex) quickly removes the 
passenger strand to generate a mature RISC complex. The core components of 
the RISC complex are Dicer, Ago2, PACT and TRBP, and both TRBP and PACT 
are critical for efficient miRNA processing, because their deletion results in 
decreased mature miRNA levels and target gene silencing (Redfern et al., 2013). 
The mechanism of the human miRNA-RISC assembly is still unclear.  
The mature miRNA is responsible for aligning the RISC complex to target mRNA 
by binding at complementary seed sequences (position 2-8) in the 3’UTR. This 
association of target mRNA with the miRNA-containing RISC most commonly 
results in down-regulation of gene expression by either repression translation or 
recruitment of protein complexes causing deadenylation and degradation of target 
mRNA. MiRNA bind to its target mRNA, repressing the translation or cleaving the 
target when is present a perfect complementarity, even if normally miRNAs bind in 
a non perfect complementary way to the 3' UTR of the target mRNAs blocking the 
translation. Through this mechanism miRNAs regulate the translation of more than 
60% of protein-coding genes. The target silencing requests the presence of the 
Ago 4 proteins suggesting that the expression levels of miRNAs are directly 
related to the expression levels of Ago proteins. All Ago proteins are capable of 
inducing translational repression and decay of target mRNAs through interaction 
with the translation machinery and mRNA decay factors, called slicer-independent  
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silencing (Ha and Kim, 2014).  
 
 
Canonical pathway of microRNA processing (Winter et al., 2009). 
 
Most of the regulation processes in which miRNAs are implicated, are not known 
or clear; the difficulty lies in the fact that a single miRNA can regulate up to few 
hundreds of different mRNA, and therefore able to regulate the expression of 
multiple proteins involved in different biological processes. 
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MiRNAs recognition of target mRNA and impairment of the formation of a polypeptide from that mRNA 
(Wilfred et al., 2007). After miRNAs recognition of the target mRNA, the  Argonaute protein helps to mediate  
translational inhibition and/or mRNA sequestration and degradation. MiRNAs (blue/purple); Argonaute 
proteins (red); target mRNA (green).  
 
1.3 MicroRNAs and Parkinson’s disease 
 
In recent years has been highlighted that epigenetic and genetic defects in 
miRNAs and their processing machinery are a common hallmark of human 
diseases, albeit other non-coding RNAs, such as small nucleolar RNAs 
(snoRNAs), PIWI-interacting RNAs (piRNAs), large intergenic non-coding RNAs 
(lincRNAs), and the heterogeneous group of long non-coding RNAs (lncRNAs) 
might also affect the development of many different human disorders.  
The miRNAs are found in high abundance within the nervous system, around 70% 
of all miRNAs expressed by all human tissues are expressed in the brain. These 
miRNAs are found to be co-expressed with their target and often display a brain-
specific expression pattern. The miRNAs are physiologically implicated in different 
biological functions, often playing a regulatory role, including synaptic plasticity 
and neurogenesis. Deregulation or dysfunction of miRNAs in the 
neurodegenerative disorders and their emerging role in Alzheimer’s disease, 
Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease 
pathogenesis is increasingly recognized.  
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1.3.1 MiRNAs as regulators of PD genes 
 
The first evidence of miRNAs implication in Parkinson’s disease is to attribute to 
Kim and his group (Kim et al., 2007) showing a reduction of locomotion and 
symptoms reminiscent of human PD as a consequence of a deletion of Dicer in 
dopaminergic neurons in transgenic mice. Another example is miR-133b, which 
was shown to be downregulated in PD patients and be involved in regulation of 
maturation processes and function of dopaminergic neurons in midbrain (Kim et 
al., 2007). The mRNA expression levels of alfa-synuclein are repressed by miR-7, 
which shows decreased levels in PD-associated neurotoxin cell and rodent models 
(Junn et al., 2012). Furthermore, associated with PD, is the disruption of the 
binding site for miR-433 in FGF20 gene and the over-expression of FGF20 is 
correlated with high levels of SNCA (Wang G et al., 2008). MiR-34b/c has been 
found down-regulated in PD brains, underlying mitochondrial dysfunction and 
oxidative stress (Miñones-Moyano et al., 2011). Alfa-synuclein is negatively 
regulated by mirR-7 and miR-153, suggesting a possible approach to limit or solve 
PD progression.  
The groups of Maciotta and Maffioletti (Maciotta et al., 2013; Maffioletti et al., 
2014) elaborated an interesting and exhaustive summary of the miRNAs 
implicated in PD. Even if to date there are limited findings on deregulated miRNAs 
associated to PD, they are a promising source of new diagnostic, prognostic and 
therapeutic tools which could also help to understand more clearly its 
pathophysiology.  
 
MiRNAs and specific target genes involved in PD. Table modified by Maciotta et al., 2013. NDDs 
(neurodegenerative disorders). 
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MiRNAs deregulation in PD. Table modified by Maciotta et al., 2013. NDDs (neurodegenerative disorders). 
 
1.3.2 MicroRNAs as potential biomarker for Parkinson’s disease 
 
The Biomarkers Definition Working Group (Biomarkers Definition Working Group, 
2001) has defined as biomarker “a characteristic that is objectively measured and 
evaluated as an indicator of normal biologic processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention”. It is possible to think to a 
biomarker as a trait biomarker when indicates susceptibility to a disease, a state 
biomarker if it defines the diagnostic of a disease, or a rate biomarker, when it 
tracks progression of the disease (Chahine et al., 2014). It means that a biomarker 
is represented by a biochemical or molecular element expressed during a 
physiological or pathological condition in a specific stage of life, that can be used 
to diagnose, prognosticate and monitor the disease itself before and/or during the 
therapy. The identification of specific biomarkers at early stages of the disease 
could lead to early drug treatment, delaying the progression of the disease, and 
monitoring the treatment. Moreover a biomarker should meet requirements such 
as easy accessibility, sufficiently high specificity and sensitivity, low costs and 
standard applicability in the laboratories.  
 
Most of the methods aimed to discover new biomarkers include proteomics (study 
of structure and function of specific proteins), metabolomics (study of chemical 
metabolic processes through the measurement of small-molecule metabolites), 
and gene expression profiling. 
Regarding the proteomics, there are several studies applied to cerebrospinal fluid 
for PD. Challenges for developing new protein-based biomarkers include the 
complexity of protein composition in body fluids, the diversity of post-translational  
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modifications, which can affect the accuracy of measurement, the low relative 
abundance of many proteins of interest, the sequence variations among different 
clinically relevant species, and the difficulties in developing suitable high-affinity 
detection agents, even if this method is expensive and time-consuming (Etheridge 
et al., 2011). 
Microarrays, next generation sequencing (NGS) and quantitative real-time PCR 
(qRT-PCR) are widely used in the gene expression profiling; to date NGS remains 
expensive and labor intensive, both for the sample preparation and for data 
analysis, a microarray approach generally require more starting material than qRT-
PCR. 
MicroRNAs are strong and specific gene regulators and therefore promising 
candidates to be diagnostic biomarkers and as well potential therapeutic targets.  
They are stable in the bloodstream and their expression levels changes as a 
consequence of cellular damage or tissue injury. In fact, because of the proximity 
of the biological fluids to cells, the biochemical content of the fluids reflects the 
biological conditions of the cells and gives us information about the pathological 
status. For the present study it was decided to consider peripheral blood and 
plasma as potential miRNAs diagnostic sources as they are readily obtainable and 
as they reflect dynamically a system-wide biology (Liew et al., 2006). MiRNAs are 
highly abundant, tissue-specific (some miRNAs are specific to tissues or to 
biological stages), quantifiable, stable, with no post processing modifications. In 
the laboratory, the use of miRNAs as biomarkers could be advantageous, as they 
are stable in different extreme conditions, like for example high temperatures, high 
or low pH, extended storage, freeze-thaw cycles, and resistant to degradation by 
RNase-rich blood environment (Jin et al., 2013). Once blood samples are 
processed and plasma is collected, the miRNAs are stable at room temperature up 
to 24h, but it is not still clear whether the time duration between blood collection 
and the processing of plasma can affect miRNAs expression levels. For that 
reason in our study were standardized the processing conditions, defined after 
different time-tests of plasma processing (data not shown). 
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MicroRNAs have a lower complexity than proteins, which facilitates their 
exploration. Last but not least an important factor to consider, is that blood and 
plasma sample collection, containing miRNAs, is a minimal invasive process and 
costly efficient, and the levels of specific miRNAs can be measured by commonly 
standardized laboratory methods. All these characteristics make miRNAs 
attractive candidates biomarkers.  
 
In order to develop a precise and sensitive PBMCs/plasma-miRNA based 
diagnostic biomarker it’s necessary to focus on different technical aspects, such as 
the miRNA qRT-PCR assay, specific extraction methods in order to minimize the 
degradation process, quantification analysis, and the usage of correct endogenous 
genes for the expression data normalization. 
 
1.4 Common miRNAs normalization procedures in blood 
 
The importance of the miRNAs normalization is currently broadly recognized. To 
date do not exist an established and standardized reliable reference gene set to 
use as normalizers for miRNA profiling study in peripheral blood and plasma PD 
samples. The normalization process consist in the comparison of the expression 
levels of the investigated miRNAs (case-control groups) with the expression of an 
endogenous reference gene in order to obtain a relative quantification of the 
investigated miRNAs (Wotschofsky et al., 2011). 
The common methods applied for normalization are described as follow 
(Sheinerman et al., 2013) (i) the use of synthetic miRNAs spiked in the sample 
before the miRNA extraction (e.g. C. Elegans or plant miRNAs which are not 
endogenous in the analyzed sample). By adding the same amount of spiked-in 
RNAs with an equal volume of sample, a stable reference control is obtained. This 
approach allows compensating for variability caused by RNA extraction step and 
the possible presence of inhibitors during the qRT-PCR process. They can be 
used as well to monitor the efficiencies of single step in the miRNA extraction, 
retrotranscription and expression analysis; (ii) the use of stable concentrated 
endogenous miRNAs not involved either directly or indirectly in the pathology  
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under study. Ideally, the value of the endogenous miRNAs are used as reference 
by comparing their concentration between the control and affected samples group 
fluctuation; (iii) the use of endogenous small nuclear or nucleolar RNAs (snRNA 
and snoRNA) which are longer than the miRNAs and more stably expressed; (iv) 
the normalization per average of all investigated miRNAs (global mean approach); 
this approach is used mostly for miRNA microarrays studies, where a large 
number of miRNA are analyzed. 
Furthermore, the factors that can affect the efficiency of endogenous reference 
genes chosen as normalizers, could be technical factors including variability during 
the sample collection and processing, as well the presence in body fluids of 
various factors affecting miRNAs purification and qRT-PCR analysis.  
The normalization for endogenous snRNAs, snoRNAs and miRNAs is commonly 
used in blood based study, whereas in plasma based study are used miRNAs 
and/or synthetic spikes-in. At the moment different normalization approaches are 
described in literature, but at the same time no single standard normalization 
method is commonly accepted. 
 
In our study was decided to investigate snRNAs, snoRNAs, miRNAs and miRNAs 
spike-in in order to measure their stability values in all samples and choose the 
best normalization reference gene set feasible for our designed study. 
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2. OBJECTIVE 
 
The aim of the present study is to identify and characterize PBMCs and plasma 
microRNAs (miR-29a-3p, miR-29b-3p, miR-30a-5p, miR-30b-5p, and miR-103a-
3p) as potential diagnostic biomarkers for PD and verify if plasma is a suitable 
alternative/additional easy accessible resource as PD miRNA biomarker. 
 
The following specific aims were addressed:  
1. A screening of the best reference genes set to be used in an expression 
profile study in PBMCs samples from L-dopa treated PD, and drug-
naїve PD patients and evaluate the impact of different reference gene 
sets on interpretations of target miRNA expression profile. 
2. Profile the expression of miR-29a-3p, miR-29b-3p, miR-30a-5p, miR-
30b-5p, and miR-103a-3p in PBMCs and plasma samples from L-dopa 
treated PD patients and matched controls and compare their profiles; 
verify if plasma is a interchangeable and easily accessible PD 
biomarker sources. 
3.  Verify if the observed difference in miRNA expression could be the 
consequence of L-dopa treatment rather than to the PD pathogenesis 
per se, performing an expression analysis on PBMCs and plasma 
samples from drug-naïve PD patients and matched control. 
4. Perform a preliminary deep sequencing analysis on 4 PBMCs samples 
from L-dopa treated PD patients using Illumina MiSeq Next Generation 
Sequencing platform in order to discover new miRNAs. 
5. Interpret the miRNAs expression data in a biological context through a 
more sophisticated in silico target prediction. 
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3. MATERIAL AND METHODS 
 
3.1 Standard protocol approvals, registrations, and patients consensus 
 
Were enrolled 10 drug-naïve PD patients and 50 PD patients treated with L-dopa 
presenting at the Movement Disorders outpatient clinic of the General Regional 
Hospital of Bolzano (Italy). It was performed the PD diagnosis according to Gelb 
PD criteria (Gelb, Oliver, and Gilman, 1999) and were excluded all subjects with 
cognitive impairment or unable to sign the informed consent or affected by atypical 
parkinsonisms. Were enrolled 10+50 disease-free controls matched 1:1 by sex 
and age (range ± 3 years), recruited among spouses or unrelated caregivers. 
Demographic and clinical patients’ features are summarized here below. The local 
ethics committee approved the study, and all enrolled participants provided written 
informed consent to participate. 
 
Clinical details of 36 L-dopa treated PD patients, 10 drug-naïve PD patients, and disease-free matched 
controls.analyzed in PBMCs (Serafin et al., 2015). 
 
Characteristic   Measure 
Treated PD 
Patients 
(n=36)  
Controls* 
(n=36)  
Drug-Naïve 
PD Patients 
(n=10) 
Controls** 
(n=10) 
Gender        
F  nr (%) 22 (61%)  22 (61%)  4 (40%) 4 (40%) 
M  nr (%) 14 (39%)  14 (39%)  6 (60%)  6 (60%)  
AAE   Mean y ± SD 68 (11)  67 (10)  68 (7)  67 (7)  
AAO   Mean y ± SD 60 (14)  / 64 (5)  / 
Disease 
Duration 
  Mean y ± SD 7 (6)  /  4 (3)  / 
IPD 
Phenotypic 
Subtype                   
Tremor 
Dominant   
nr (%)          19 (53)  / 10 (100%) / 
Akinetic‐rigid  nr (%)  17 (47)  / 0 (0%) / 
UPDRS III  scale 0-30 Mean y ± SD 10 (7)  / 17 (10)  / 
Hoen & Yahr 
modified 
stage 
stage 1  nr (%) 17 (47)  / 4 (40%) / 
stage 1,5   nr (%) 3 (9)  / 0 (0%) / 
stage 2  nr (%) 11 (31)  / 4 (40%) / 
stage 2,5  nr (%) 2 (6)  / 2 (20 %) / 
stage 3  nr (%) 2 (6)  / 0 (0%) / 
stage 4  nr (%) 0 (0%) / 0 (0%) / 
stage 5  nr (%) 0 (0%) / 0 (0%) / 
LID   Mean y ± SD 11 (31)  / / / 
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Legend: AAE: age at evaluation; AAO: age at onset; LID: Levodopa-induced dyskinesia; * age and sex matched controls for 
Not Treated IPD Patients;** age and sex matched controls for Drug-Naïve IPD Patients; 
 
Clinical details of L-dopa treated PD patients, drug-naïve PD patients and matched unaffected controls 
analyzed in plasma and drug-naïve PD patients and matched unaffected controls analyzed in PBMCs. 
 
Characteristic   Measure 
Plasma 
cases 
(n=50) 
Plasma 
controls 
(n=50) 
Plasma 
+ 
PBMC 
cases 
(n=31) 
Plasma 
+ PBMC 
controls 
(n=31) 
Drug-
naive 
PD 
Plasma 
+ 
PBMC 
cases 
(n=10) 
Drug-
naive 
PD 
Plasma 
+ PBMC 
controls 
(n=10) 
Gender 
Female n(%) 24 (48) 24 (48) 
19 
(61.3) 
19 
(61.3) 
4(40) 4(40) 
Male n(%) 26 (52) 26 (52) 
12 
(38.7) 
12 
(38.7) 
6(60) 6(60) 
AAE   
Mean y 
(SD) 
65.2 
(10.0) 
65.2 
(10.4) 
66.5 
(10.7) 
67 (11) 68(7) 67(7) 
AAO   
Mean y 
(SD) 
58.5 
(12.7) 
- 59 (14) - 64(5) / 
Disease 
Duration 
  
Mean y 
(SD) 
6.7 (5) - 
7.1 
(5.9) 
- 4(3) / 
PD 
Phenotipic 
Subtype 
Tremor 
Dominant 
n(%) 24 (48) - 
14 
(45.2) 
- 10(100) / 
Akinetic-
rigid 
n(%) 26 (52) - 
17 
(54.8) 
- 0(0) / 
UPDRS III scale 0-30 
Mean y 
(SD) 
9.3 
(6.7) 
- 
10.1 
(7.3) 
- 17(10) / 
Hoen & Yahr 
modified 
stage 
stage 1 n(%) 26 (53) - 
13 
(43.3) 
- 4(40) / 
stage 1.5 n(%) 4 (8.2) - 3 (10.0) - 0(0) / 
stage 2 n(%) 
13 
(26.5) 
- 
10 
(33.3) 
- 4(40) / 
stage 2.5 n(%) 4 (8.2) - 2 (6.7) - 2(20) / 
stage 3 n(%) 2 (4.1) - 3 (6.7) - 0(0) / 
stage 4 n(%) - - - - 0(0) / 
stage 5 n(%) - - - - 0(0) / 
LID   n(%) 15 (30) - 
10 
(32.3) 
- / / 
Legend: cases: L-dopa treated PD patients; AAE: age at evaluation; AAO: age at onset; LID: Levodopa-induced dyskinesia; 
* age and sex matched controls for Not Treated IPD Patients;** age and sex matched controls for Drug-Naïve IPD Patients; 
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3.2 RNA isolation and quality control 
 
RNA was obtained from 2ml peripheral blood collected in Na3-citrate buffered 
Venosafe®Plastic Tubes (VF-054SBCS07, Thermo) and processed within 6 hours 
after blood collection.  
For PBMCs L-dopa treated PD patient’s samples and matched controls: 
RNA, including small RNAs was extracted from PBMCs after red blood cell lyses 
in whole blood: mix 2 ml of whole human blood added to 10 ml of RBC (red blood 
cell)-lyses buffer incubated for 15min on ice (to permit the lyses of erythrocytes), 
followed by centrifugation at 400 xg for 10 min at 4°C, in order to recover the 
leucocytes pellets; it was added 4 ml of RBC-lyses buffer to the pellet, followed by 
centrifugation at 400 xg for 10 min at 4°C, and completely removed and discarded 
the supernatant. RBC-lysis buffer in DEPC water (pH 7,4) contain 155 mM (8,29g 
/l solution) (Sigma a9434), MW= 53,49 of NH4Cl, 20 mM (1g/1l solution) (Sigma 
60339), MW=100,12 of KHCO3, 0,1 mM (0,034 g or 200 l of a 500mM ETDA 
sol/1l solution) (Sigma E5134), and MW= 372,24 of NaEDTA. 
For PBMCs drug-naive PD patient’s samples and matched controls samples: 
RNA was extracted from buffy coats previously frozen in 10% dimethyl sulfoxide 
(DMSO; cat. no. D2650; Sigma-Aldrich, Milano, Italy) as mentioned above. 
Total RNA was isolated using TRIzol reagent (cat. no. 15596-018; Life 
Technologies, Monza, Italy) according to the manufacturer’s instructions. Samples 
were standardized controlled-rate -1°C/minute cell freezing in a -80°C freezer and 
cryo-preserved in liquid-nitrogen vapour. 
RNA quality and quantity of the PBMCs samples was assessed with the 
Experion™ Automated Electrophoresis System (Bio-Rad Laboratories s.r.l., 
Milano, Italy) using the StdSens Analysis Kit (Cat.no. 7007103; Bio-Rad 
Laboratories s.r.l., Milano, Italy). All samples showed an RNA Quality Indicator 
(RQI) ≥ 7.5.  
 
Plasma from both L-dopa treated PD patients, drug-naïve PD patients, and 
matched controls was obtained centrifugating peripheral blood within 6 hours of 
blood collection in Na3-citrate buffered Venosafe®Plastic Tubes (VF-054SBCS07,  
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Thermo) for 15 minutes at 1500 g at 4°C. Total RNA, including miRNAs, was 
extracted from aliquots of 200 µl plasma, using the mirVANA PARIS kit (AM1556, 
Ambion/Life Technologies) according to the manufacturer’s instructions with few 
modifications. After the denaturation step, it was added 1.25 µl MS2 carrier (10 
165 948 001 Roche; conc. 10 A260 units = 0.8 µg/ µl, stored at -20°C), and 3.5 µl 
(0.26 fmol/ µl) of each spike-in oligo, the cel-miR-39-3p (219610, Qiagen), cel-
miR-238-3p and cel-miR-54-3p (Integrated DNA Technologies) to the 200 µl of 
starting plasma L-dopa treated PD, drug-naїve PD, and controls samples aliquots. 
After the Acid Phenol:Chloroform extraction, a second extraction step was 
performed adding 300 µl DEPC H20 to the organic phase. The pooled fractions 
were further processed according to the protocol. We stored RNA in DEPC H20 at 
-80°C. 
The RNA yield from plasma was too low to be quantified by traditional methods. 
 
3.3 Reverse Transcription and quantitative real time PCR 
 
Reverse transcription (RT) and expression analysis (qRT-PCR) of miR-29a-3p, 
miR-29b-3p, miR-30a-5p, miR-30b-5p, and miR-103a-3p was performed on blood 
samples from L-dopa treated PD patients, drug-naïve PD patients and matched 
controls, according to the following protocol. The RT reactions were performed on 
7 ng of total RNA using a TaqMan miRNA Reverse Transcription Kit (Cat.no. 
4366597; Life Technologies, Monza, Italy) and miRNA-specific stem-loop primers 
in a scaled down 10 µl reaction, according to the manufacturer’s instructions. The 
thermal cycling parameters were 30 min at 16°C, 30 min at 42°C, 5 min at 85°C. 
All RT-qPCR reactions were performed in triplicate on a 96CFX instrument (Bio-
Rad Laboratories s.r.l., Milano, Italy) in scaled down 10 µl reaction volumes using 
0.5 ng of RT product per reaction, Universal MasterMixII no UNG, and TaqMan® 
small RNA assays (Cat.no. 4440048 and, 4427975 Life Technologies, Monza, 
Italy), according to the manufacturer’s instructions. The thermal cycling 
parameters were 10 min at 95°C followed by 40 cycles of 15 sec at 95°C and 1 
min at 60°C. The relative amplification efficiencies range between 96% and 109%. 
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Reverse transcription and expression analysis of miR-29a-3p, miR-29b-3p, miR-
30a-5p, miR-30b-5p, and miR-103a-3p was performed on plasma samples from L-
dopa treated PD patients, drug-naïve PD patients and matched controls, according 
to the following protocol. The RT reactions were performed on 2.5 ul of total RNA 
using a TaqMan miRNA Reverse Transcription Kit (Cat.no. 4366597; Life 
Technologies, Monza, Italy) and miRNA-specific stem-loop primers in a scaled 
down 7.5 µl reaction, according to the manufacturer’s instructions. The thermal 
cycling parameters were 30 min at 16°C, 30 min at 42°C, 5 min at 85°C. All qRT-
PCR reactions were performed in triplicate on the 96CFX instrument (Bio-Rad 
Laboratories s.r.l., Milano, Italy) in scaled down 10 µl reaction volumes using 2.5 µl 
of 1:15 diluted RT product per reaction, Universal MasterMixII no UNG, and 
TaqMan® small RNA assays (Cat.no. 4440048 and, 4427975 Life Technologies, 
Monza, Italy), according to the manufacturer’s instructions.  
All reactions were performed on hard shell PCR plates (Bio-Rad Laboratories Inc. 
Part.No HSP9645), sealed with adhesive Microseal ‘B’ Films (Bio-Rad 
Laboratories Inc. Part.No RSN 102595). One sample was used as an internal 
reference to monitor plate to plate variation, and a NTC (no template control) was 
included on each plate. The thermal cycling parameters were 10 min at 95°C 
followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C.  
PCR amplification efficiency for all target and reference genes was determined 
from the slope of the log-linear portion of the calibration curves. 
 
3.4 Standard curve efficiency 
 
A serial dilution of cDNA, reverse transcribed from total RNA extracted from 
pooled samples, was used to plot the standard curves for each gene assay. The 
relative expressions of miRNAs were normalized using RNU24 and Z30 as 
reference genes set for PBMCs samples, whereas for plasma samples were used 
spike-in oligos cel-miR-39-3p, cel-miR-54-3p and cel-miR-238-3p. It has been 
taken into account amplification efficiency arranges between 80% and 100% with 
a r2 of 0.96 and 0.99. 
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3.5 qRT-PCR normalization and relative quantification of miRNAs 
 
TaqMan Small RNA Assays are pre-formulated primer and probe sets designed to 
detect and quantify small RNAs, including mature microRNAs. During the 
annealing the TaqMan probe binds to the target sequence and when the quencher 
is near to the fluorescence dye, no signal is detectable. During the combined 
annealing/extension step of the amplification reaction, Taq polymerase degrades 
the probe that has annealed to the template. The reporter is released and 
separated from the quencher. The increase in fluorescence can be monitored 
following the threshold cycle (Ct) during a PCR reaction, which reflects the cycle 
number at which we have a detectable fluorescence. The fluorescence signal is 
proportional to the amplified DNA amount and it is measured at the end of each 
cycle.  
The NormFinder (Andersen et al., 2004) and GeNorm (Vandesompele et al. 2002) 
algorithms, together with the comparative delta-Ct approach (Silver et al., 2006) 
were used to assess the variance in expression levels and to identify the most 
stable and reliable reference genes. The relative expression levels were assessed 
using the Bio-Rad CFX Manager v1.6/v3.1 (Bio-Rad Laboratories s.r.l., Milano, 
Italy) and qBasePlus (Biogazelle) software using RNU24 and Z30 as normalizers 
for the PBMCs L-dopa treated PD samples, drug-naïve PD samples and matched 
controls (chosen among RNU24, Z30, RNU6B and miR-103-3p), and cel-miR-39-
3p, cel-miR-238-3p and cel-miR-54-3p for the plasma L-dopa treated PD samples, 
drug-naïve PD samples and matched controls (chosen among cel-miR-39-3p, cel-
miR-238-3p, cel-miR-54-3p and miR-191-5p). The relative amplification 
efficiencies were ranged between 90% and 109%. 
 
Minimum Information for Publication of Quantitative Real Time PCR Experiments 
(MIQE) guidelines (Bustin et al., 2009) were followed for description of samples, 
RNA extraction, RT-qPCR and data analysis. 
 
TaqMan® MicroRNA assays. Gene name and relative TaqMan® MicroRNA assays, 
sequence. 
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miRNA 
mirBase Accession/ NCBI 
Ref Sequence 
Assay ID Mature miRNAs Sequences 
miR-29a-3p MIMAT0000086 2112 UAGCACCAUCUGAAAUCGGUUA 
miR-29b-3p MIMAT0000105 413 UAGCACCAUUUGAAAUCAGUGUU 
miR-30a-5p MIMAT0000087 417 UGUAAACAUCCUCGACUGGAAG 
miR-30b-5p MIMAT0000420 602 UGUAAACAUCCUACACUCAGCU 
miR-103a-3p MIMAT0000101 439 AGCAGCAUUGUACAGGGCUAUGA 
miR-191-5p MIMAT0000465 2299 CAACGGAAUCCCAAAAGCAGCUG 
cel-miR-39-
3p MIMAT0000010 200 UCACCGGGUGUAAAUCAGCUUG 
cel-miR-54-
3p MIMAT0000025 1361 UACCCGUAAUCUUCAUAAUCCGAG 
cel-miR-238-
3p MIMAT0000313 248 UUUGUACUCCGAUGCCAUUCAGA 
 
3.6 Statistical Analysis  
 
In order to determine the expression stability of the PBMCs (RNU24, Z30, RNU6B, 
miR-103a-3p) and plasma (Cel-miR-39-3p, Cel-miR-238-3p, Cel-miR-54-3p, miR-
191-5p) candidate reference genes, statistical analyses of their expression levels 
across all samples were performed using three different methods: NormFinder and 
GeNorm algorithms, and comparative delta-Ct method. NormFinder computes a 
stability measure and the lowest value indicates the most stable gene expression. 
GeNorm compute M stability values, calculated assuming the specific efficiency for 
each gene assay where the lower M values indicate the most stable gene 
expression. Comparative delta-Ct compares relative expressions of pairs of genes 
within each sample set and ranks stability of reference genes according to the 
repeatability of the gene expression difference. 
To determine if different reference gene sets could affect the direction of the target 
miR-29a-3p and miR-30b-5p, the distribution of the difference of the expression 
levels between cases and controls, within each matched pair and normalized with 
different combinations of reference genes, was checked using a Skewness-
Kurtosis test for normality. A subset of the ladder of powers for variable 
transformation in case of departure from normality was evaluated. Relative 
expression of miR-29a-3p and miR-30b-5p was analyzed using a Wilcoxon  
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matched-pairs signed-ranks test. Although 15 tests for each microRNA were 
performed, no adjustment for multiple comparisons was done. This is because in 
practice the only test that would have been performed is the one based on data a 
priori normalized for the best reference gene combination. Spearman’s rank 
correlation coefficients were computed on Ct reference gene data and on 
normalized miR-29a-3p and miR-30b-5p data. GeNorm analysis was performed 
using Biogazelle’s QbasePLUS software (Bio-Rad Laboratories Inc.) and 
NormFinder analysis was performed using “NormFinder.xla”, a Microsoft Excel-
based Visual Basic application.  
Relative expression of PBMCs miRNAs was assessed using the BIORAD CFX 
manager v1.6 and qBasePlus (Biogazelle) software. Basic descriptive statistics, as 
means and standard deviations, were generated to the distribution of the 
difference of expression levels showing no departure from normality with a 
Skewness-Kurtosis test. For each miRNA, the mean and the standard deviation 
(SD) of the differences of the relative expressions between each case and its 
matched control were used as input to calculate the appropriate sample size 
needed for a second experiment on untreated patients. Sample size was 
calculated in order to 
achieve 80% power with alpha = 0.05, and was performed using the command 
sampsi implemented in Stata 12. All the analyses were performed using Stata 12 
(StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: 
StataCorp LP).  
 
Relative expression of plasma miRNAs was assessed using the Biorad CFX 
manager v3.1 and qBasePlus (Biogazelle) software. It was checked the normality 
of the distribution of the differences of the relative expression levels within each 
matched set using a Skewness-Kurtosis test. 
For the plasma and PBMCs L-dopa treated PD samples and matched controls 
have been calculated the summary statistics as mean, standard deviation, median 
and interquartile range (IQR). Outliers have been detected, but since no technical 
reasons justifying their presence was identified, they were kept in the analysis. 
Data have been analyzed using a two-tailed paired t-test and a non-parametric  
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Wilcoxon matched-pairs signed-ranks test, when the differences of expressions 
within each set were not normally distributed. An exploratory subgroup analysis 
was also performed in males and in females groups separately. 
For the plasma and blood drug-naïve PD patients and matched controls, the 
median and interquartile range was provided to summarize data. Data have been 
analyzed a non-parametric Wilcoxon matched-pairs signed-ranks test, applied due 
to the small sample size. Sample size needed to achieve a power of 80%, with 
alpha = 0.05, was calculated for the deregulated miRNAs, based on the effect 
sizes and the standard deviations observed for L-dopa treated patients using 
sampsi Stata command.  
 
All the PBMCs analyses were performed using Stata 12 (StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP) and plasma 
analysis using Stata 13 (StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP). 
 
3.7 Bioinformatic analysis: target prediction and priorization 
 
It was applied a computational approach for the identification and prioritization of 
candidate targets of miR-29a-3p, miR-30b-5p, and miR-103a-3p, and used 
multiple miRNA target resources for the identification of candidate targets. It was 
prioritized the candidates likely to be involved in PD based on a “guilt by 
association” principle by searching for links to PD-related genes and processes. 
Different scores were computed from the multiple types of evidence. In addition, 
were compared the ranked candidates to sets of PD-related genes and to results 
obtained with Endeavour, an established prioritization method. 
Were collected experimentally validated miRNA targets from multiple sources, in 
particular, a manual literature search of reported target genes (labeled CBM) and 
the public databases TarBase (version 6.0) (Vergoulis et al., 2012), miRTarBase 
(retrieved on 2013-02-06) (Hsu et al., 2011), miRWalk (retrieved on 2013-02-05) 
(Dweep et al., 2011), and miRecords (retrieved on 2013-02-05) (Xiao et al., 2009). 
Were collected predicted miRNA targets from DIANA-microT-CDS (retrieved on  
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2012-01-18) (Reczko et al., 2012), miRmap (retrieved on 2013-02-04) (Vejnar et 
al., 2012), miRDB (version 4.0) (Wang X et al., 2008), TargetScan (retrieved on 
2013-02-04) (Friedman et al., 2009) and miRanda (release 2010-08) (Betel et al., 
2010).  
Custom panels of PD-related processes and genes were compiled and applied for 
prioritization. GOPD is a panel of PD-related processes, AVPD is a panel of genes 
related to PD, and CPD is a list of candidate PD genes. AVPD and CPD are non-
overlapping sets. Were compared the candidate miRNA targets to additional sets 
of PD-related genes, in particular sets of Parkin interactors from interaction 
screens (ParkinTAP, ParkinInt), or Parkin dependent ubiquitylation targets 
(ParkinUBQ). Given the known role of mitochondria function in PD (Arduino et al., 
2011), we used also a set of mitochondrion related genes (Mito) to annotate the 
results. Were collected different scores from the multiple types of evidences. 
Several scores summarize the validated annotations (V_PMID) and predictions 
(PP and PF scores) from miRNA target resources. The GOSlim score allows the 
identification of candidate genes annotated to PD-related processes. BPscore 
quantifies the functional relationship to PD-related genes, PPI and Cpx summarize 
the number of protein interactions and complexes with PD-related proteins. Were 
used the InSet score to identify candidates in PD panel, and used the different 
scores to compute a combined score (CRscore) applied to rank the candidates. 
3.8 Library preparation for NGS analysis 
 
500ng/µl of total RNA was used to prepare the library according to the 
manufacturer’s instructions (Nebnext Small Multiplex Library Preparation Prep Set 
for Illumina, NEB#E7300S/L, New England Biolab Inc.). The size-selection 
cleaning of the library was done first with a ratio 1:1.2X and 1:3.7X volume 
magnetic beads (AMPure XP Beads, Agencourt) and a second time, as suggested 
by the manufacturer, with a ratio 1:1.3X and 1:3.7X volume magnetic beads. The 
quality and quantity of the cleaned library were measured using KAPA Library 
Quantification Kit for Illumina Sequencing Platform (Resnova), according to the 
manufacturer’s instructions on the 96CFX instrument (Bio-Rad Laboratories s.r.l., 
Milano, Italy). 12.5pM of library was prepared according to the manufacturer’s  
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instruction of the Illumina TruSeq small RNA Library Prep kit and loaded on the 
Illumina MiSeq® System, NGS platform (Illumina), according to the manufacturer’s 
instructions. 
3.9 Bioinformatic’s analysis workflow of the NGS data output 
 
A multiple repetition of cutadapt was used to remove all adapters and technical 
sequence artefacts. The cleaned sequences were mapped to mature miRNA and 
snoRNA with bowtie2 in local mode (allowing for soft clipping of reads at the ends) 
and uniquely matching reads with no mismatches were selected. Differential 
expression analysis was done with DESeq2 and EdgeR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 26  
 
Results
 
4. RESULTS 
 
4.1 Identification of a reliable set of endogenous reference genes for PBMCs 
miRNAs expression studies in Parkinson disease’s 
In order to identify a reliable set of endogenous reference genes to use on PBMCs 
samples for miRNA expression studies in Parkinson Disease’s as normalizer, all 
the raw expression data were analyzed in a second moment using not only the 
NormFinder (Andersen et al., 2004) and the GeNorm (Vandesompele et al. 2002) 
algorithms, but also the comparative delta-Ct method (Silver et al., 2006).  
GeNorm and Normfinder allow the ranking of candidate reference genes according 
to their stability and indicate the optimal number and combination of reference 
genes required for accurate normalization of gene expression. Comparative delta-
Ct compares relative expressions of pairs of genes within each sample set and 
ranks stability of reference genes according to the repeatability of the gene 
expression difference. Samples were grouped to allow direct estimation of 
expression variation, ranking genes according to the similarity of their expression 
profiles by using a model-based approach. NormFinder takes into account inter- 
and intra-group variation for normalization factor calculations avoiding 
misinterpretation caused by artificial selection of co-regulated genes. GeNorm 
computes an M value describing the variation of a gene compared to all other 
candidate genes. Similarly to the NormFinder stability value, lower M values 
indicate stable gene expression. Specifically, stable reference genes are 
supposed to have an M value smaller than 1.5.  
The results of the expression stability assessment of Z30, RNU24, RNU6B and 
miR-103a-3p among all analyzed samples are reported in Tables 1 and 2, showing 
the results of the comparative delta-Ct method and the comparison with the 
NormFinder and GeNorm results. Independently on the method used, the gene 
ranking remained unchanged, thus indicating that Z30 and RNU24 were the best 
reference genes to use as normalizer (Serafin et al., 2014). The combination of 
Z30 and RNU24 was selected as the best reference genes set among all the 
others to use in our study. This combination showed the smallest and therefore  
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best stability values among all the other combinations of reference genes, 
whereas the worst combination was attributed to RNU6B and miR-103a-3p.  
Combination Mean delta-Ct SD Mean SD 
RNU24 vs Z30 −1.53 0.58 0.93 
RNU24 vs RNU6b −2.26 1.09  
RNU24 vs miR-103a-3p −0.71 1.12  
Z30 vs RNU24 1.53 0.58 0.93 
Z30 vs RNU6B −0.73 0.99  
Z30 vs miR-103a-3p 0.82 1.23  
RNU6B vs Z30 0.73 0.99 1.25 
RNU6B vs RNU24 2.26 1.09  
RNU6B vs miR-103a-3p 1.62 1.66  
miR-103a-3p vs Z30 −0.82 1.23 1.34 
miR-103a-3p vs RNU24 0.71 1.12  
miR-103a-3p vs RNU6B −1.62 1.66  
Table 1. Comparison of candidate reference genes expression stability using the comparative delta-Ct 
method. Mean delta-Ct = Ct target – Ct reference; SD = standard deviation of the mean; mean SD = mean of 
the calculated standard deviations (Serafin et al., 2014). 
Gene Comparative delta-Ct NormFinder GeNorm 
RNU24 0.93 0.007 0.839 
Z30 0.93 0.016 0.841 
RNU6B 1.25 0.033 1.112 
miR-103a-3p 1.34 0.018 1.310 
Table 2. Comparison of the stability values estimated using the comparative delta-Ct, NormFinder and 
GeNorm algoritms. Comparative delta-Ct = mean of the standard deviations (SD); NormFinder = computes a 
stability measure and the lowest value indicate the most stable gene expression; GeNorm: M stability values, 
calculated assuming the specific efficiency for each gene assay, the lower M values indicate the most stable 
gene expression (Serafin et al., 2014). 
4.2 Different combinations of reference genes set have a strong impact on 
the relative expression levels observed for both miR-29a-3p and miR-30b-
5p 
We tested the effect of using different combinations of reference genes on the 
relative expression values using miR-29a-3p and miR-30b-5p as targets, which 
were found to be deregulated in PD in previous studies (Margis et al., 2011;  
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Martins et al., 2011). As reported in Table 3, an increased relative expression of 
miR-29a-3p and miR-30b-5p in L-dopa treated PD patients in comparison to 
disease-free matched controls could be observed using the best reference gene 
set Z30/RNU24. The same trend could be observed using Z30, RNU24 and 
RNU6B as reference genes, either alone or in different combinations. The usage 
of miR-103a-3p alone as reference gene resulted in an opposite effect in target 
miRNAs expression direction and it was sufficient to completely reverse the 
direction of the expression difference between cases and controls of the 
investigated miRNAs (miR-29a-3p median difference = −0.58, IQR = −1.33; −0.05, 
p = 0.0003 and miR-30b-5p median difference = −1.16, IQR = −2.53; 0.23, p = 
0.0005). The inclusion of miR-103a-3p in any other combination of reference 
genes systematically worsened the observed p values. This effect was clearly 
visible with the addition of miR-103a-3p to the set Z30 and RNU24 (Table 3), 
which had a strong impact on the results observed for both miR-29a-3p and miR-
30b-5p, with the p value of miR-29a-3p changing from p = 0.0032 to p = 0.5473 
and the p value of miR-30b-5p changing from p = 0.0009 to p = 0.3422, thus 
underling the importance and the complexity of the choice of reference genes set 
(Serafin et al., 2014). Indeed, the relative expression levels of miR-29a-3p and 
miR-30b-5p were not always well correlated with each other, but some differences 
could be observed, depending on the reference gene set used for normalization 
(Table 3). 
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Reference gene 
miR-29a median of 
difference (IQR) 
P value miR-29a 
miR-30b median of 
difference (IQR) 
P value miR-30b 
Z30 0.76 (−0.23; 2.22) 0.0048 1.75 (0.17; 3.62) 0.0007 
RNU24 0.39 (−0.08; 1.34) 0.0151 0.96 (−0.52; 3.39) 0.0075 
RNU6B 0.98 (−0.17; 2.12) 0.0007 2.66 (0.2; 4.05) 0.0001 
miR-103a −0.58 (−1.33; −0.05) 0.0003 −1.16 (−2.53; 0.23) 0.0005 
Z30- miR-103a −0.02 (−0.65; 0.6) 0.7997 0.01 (−1.14; 1.32) 0.8221 
Z30-RNU24* 0.68 (−0.17; 1.74) 0.0032 1.74 (0.05; 4.26) 0.0009 
Z30-RNU24-  
0.18 (−0.48; 0.71) 0.5473 0.22 (−1.1; 1.63) 0.3422 
miR-103a            
Z30-RNU24-RNU6B-  
0.38 (−0.31; 1.23) 0.0511 1.05 (−0.31; 2.41) 0.0092 
miR-103a 
RNU24-RNU6B 0.85 (−0.02; 1.77) 0.0011 2.37 (0.2; 3.47) 0.0004 
RNU24- miR-103a         −0.35 (−0.75; 0.15) 0.0645 −0.7 (−1.54; 1.13) 0.2372 
RNU24-RNU6B-  
0.12 (−0.31; 0.91) 0.2097 0.61 (−0.44; 1.95) 0.0494 
miR-103a 
RNU24-RNU6B-Z30 0.74 (−0.08; 1.86) 0.0013 2.02 (0.1; 3.95) 0.0003 
RNU6B- miR-103a 0.04 (−0.41; 0.66) 0.3962 0.51 (−0.4; 1.19) 0.0939 
RNU6B-Z30 0.79 (−0.1; 1.98) 0.0011 2.44 (0.17; 3.8) 0.0003 
RNU6B-Z30-  
0.31 (−0.36; 1.01) 0.0733 1.02 (−0.3; 1.99) 0.0119 
miR-103a 
*Best set of reference genes. 
Table 3. Changes in the results of the analyses depending on the choice of the reference genes. The 
median of difference is calculated as median (expression in cases – expression in controls) within each 
matched case–control set and it is indicated for a descriptive purpose. IQR = interquartile range. P values 
were computed using a Wilcoxon matched pairs signed-ranks test (Serafin et al., 2014). 
 
4.3 First evidence of miR-103a-3p over-expression and deregulation of miR-
29a-3p and miR-30b-5p in PBMCs samples from L-dopa treated PD 
patients 
In order to identify miRNAs as potential diagnostic PBMCs biomarkers for PD was 
assessed the relative expression for the promising miRNAs, miR-29b-3p, miR-
30b-5p, miR-29a-3p, and miR-30a-5p from L-dopa treated PD patients in 
comparison with unaffected matched controls. Based on the literature we selected 
small nucleolar/nuclear RNAs (RNU24, Z30, RNU6B) and miR-103a-3p as 
candidate normalizers. Expression levels of these candidate reference genes were 
analyzed by geNorm and NormFinder algorithms to select the best endogenous 
candidate controls. RNU24 and Z30 were selected as the best reference genes  
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set to use for normalization, whereas the miRNA-103a-3p, used by Martins and 
collaborators (Martins et al., 2011) as endogenous control, showed a high 
variance in expression. Moreover, miRNA-103a-3p is a member of the miR-15/107 
group, involved in several physiological functions and pathologies, including 
neurodegenerative diseases. For these reasons, miR-103a-3p has been included 
in our study as a target rather than as a reference gene.  
 
As reported (Table 4, Figure 1), we found a significant increase in relative 
expression of miR-29a-3p, miR-30b-5p in peripheral blood samples from L-dopa 
treated PD patients. This finding was unexpected, since in previous papers 
(Martins et al., 2011; Margis et al., 2011) was shown a decreased expression 
levels for miR-29a-3p and miR-30b-5p in PD patients. Furthermore, we 
demonstrated for the first time an over-expression of miR-103a-3p in PBMCs 
levels from L-dopa treated PD patients (Table 4; Figure 1). 
 
miRNA                    
N pairs = 36 
Mean Difference within 
each pair (95% CI) 
P-Value Paired t-test 
miR-29a-3p 0.69 (0.23; 1.15) 0.005 
miR-29b-3p 0.26 (-0.28; 0.79) 0.339 
miR-30a-5p 0.12 (-0.14; 0.37) 0.364 
miR-30b-5p 1.76 (0.68; 2.84) 0.002 
miR-103-3p 1.80 (1.27; 2.33) <0.0001 
Table 4. Results of miRNA expression analysis on 36 PBMCssamples from L-dopa treated PD patients 
and unaffected matched controls (Serafin et al., 2015); CI= interval of confidence 
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Figure 1. Pair plots of the expression analysis on 36 PBMCs samples from L-dopa treated PD patients 
and disease-free matched controls. The plots show the difference between cases and controls within each 
pair, hence accounting for matching. The horizontal zero line indicates no difference within the pair. 
Differences have been sorted in ascending order to allow a better visualization (Serafin et al., 2015). 
 
4.4 Trend of miR-30a-5p over-expression in plasma samples from L-dopa 
treated PD patients 
To assess whether plasma is a suitable alternative/additional easily accessible 
resource for PD miRNA biomarkers, we performed an exploratory expression 
analysis on 31 plasma samples from L-dopa treated PD patients, coming from the 
same individuals already analyzed in PBMCs, for miR-29a-3p, miR-29b-3p, miR-
30a-5p, miR-30b-5p and miR-103a-3p.  
 
The first step was to assess the protocol for the extraction of miRNAs from plasma 
L-dopa treated PD patients. For the expression analysis, a different normalization 
approach was selected, because of the absence in plasma of the small non-coding 
nuclear/nucleolar RNAs (RNU24 and Z30) used previously as reference genes in 
PBMCs expression analysis on L-dopa treated PD patients. 
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Based on the literature, we selected miR-191-5p (Cardo et al., 2013; Geekiyanage 
et al., 2012), and three exogenous C.elegans spike-in miRNAs (cel-miR-39-3p, 
cel-miR-54-3p and cel-miR-238-3p) (Kang et al., 2012) as candidate normalizers. 
Using GeNorm and NormFinder algoritms, we revealed a high expression 
variability of miR-191-5p in our data (data not shown) and we decided to use 
exclusively C.elegans spike-in miRNAs for normalization.  
This synthetic miRNAs, named spike-in, are to be added into the plasma samples 
before the extraction step of miRNAs. In that way the expression analysis should 
be more sensitive because the same quantity of spike-in is added in equal 
measure to all the samples.  
 
The exploratory analysis performed on 31 plasma samples from L-dopa treated 
PD patients and disease-free controls (matched 1:1 by sex and age) showed a 
borderline significant over-expression of miR-30a-5p (p=0.0745) (Table 6). 
Moreover, we demonstrated that miR-29b-5p, normally expressed in PBMCs, was 
not detectable in plasma samples from L-dopa treated PD patients, nor in the 
plasma of the controls. 
 
4.5 Confirmation of the exploratory data obtained in the 31 plasma samples 
from L-dopa treated PD patients in an enlarged sample size 
Due to the low abundance of miRNA levels in plasma compared to PBMCs, and in 
order to confirm the exploratory data obtained in the 31 L-dopa treated PD plasma 
samples, it has been enlarged the sample size from 31 to 50 of the plasma 
samples from L-dopa treated PD patients and unaffected matched controls.  
 
The expression analysis showed a borderline significant over-expression for miR-
30a-5p (p=0.054) whereas the other miRNAs were not deregulated (Table 5; 
Figure 2). These data confirmed the previously expression analysis on 31 plasma 
samples from L-dopa treated PD patients and matched unaffected controls where 
miR-30a-5p showed also an up-regulation trend (p= 0.0745). 
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Moreover, we confirmed that miR-29b-3p was not detectable in L-dopa treated PD 
plasma samples. 
 
miRNA                        
N pairs = 50 
Mean Difference within each 
pair (95% CI) 
P value                              
paired t-test 
miR-29a-3p 0.08 (-0.16; 0.31) 0.5118 
miR-29b-3p Not found in plasma - 
miR-30a-5p 0.17 (-0.003; 0.35) 0.054 
miR-30b-5p -0.04 (-0.23; 0.15) 0.6781 
miR-103a-3p -0.04 (-0.19; 0.11) 0.5927 
Table 5. Expression of miRNA levels in 50 plasma samples from L-dopa treated PD patients and their 
matched controls; a two-tailed paired t-test was used to analyze data.  
 
 
 
Figure 2. Pair plots representing miRNA expression data in 50 matched plasma pairs. Is shown the 
difference of miRNA expression (treated case – control) within each pair. The horizontal zero line indicates no 
difference in miRNA expression within the pair. For each miRNA, data have been sorted in ascending order 
for a better visualization. 
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4.6 Different miRNA expression profiles between PBMCs and plasma 
samples from L-dopa treated PD patients 
The plasma and PBMCs samples derived from the same individuals, allowing a 
direct comparison of the expression profiles in PBMCs and plasma, revealing clear 
differences for all analyzed miRNAs (Table 6) in L-dopa treated PD patients and 
unaffcted matched controls.  
 
We observed a significant up-regulation of miR-29a-3p, miR-30b-5p and miR-
103a-3p in PBMCs samples from L-dopa treated PD patients, whereas no 
deregulation of these miRNAs were observed in plasma samples from L-dopa 
treated PD patients, where only miR-30a-5p showed a borderline significant over-
expression (p=0.0745) (Table 6), thus indicating that different miRNA expression 
profiles can be observed in plasma and PBMCs samples from L-dopa treated PD 
patients and concluding that plasma is not an interchangeable source for miRNAs 
biomarkers. 
miRNA N 
pairs = 31 
Median and IQR 
of the differences 
plasma 
P-value Wilcoxon 
plasma 
Mean 
Difference 
within each set 
(95% CI) 
PBMCs 
P-value 
paired t-test 
PBMCs 
Concordance 
PBMCs/plasma 
miR-29a-3p 0.14 (-0.37; 0.64) 0 .6807 0.52 (0.02; 1.01) 0.0418 Discordant 
miR-29b-3p 
Not found in 
plasma 
Not found in plasma 
0.26 (-0.34; 
0.85) 
0.3888 - 
miR-30a-5p 0.22 (-0.19; 0.6) 0.0745 
0.05 (-0.23; 
0.32) 
0.7361 Discordant 
miR-30b-5p -0.03 (-0.26; 0.31) 0.7989 1.59 (0.46; 2.72) 0.0075 Discordant 
miR-103-3p -0.1 (-0.3; 0.11) 0.217 1.61 (1.05; 2.17) <0.0001 Discordant 
Table 6. Comparison of miRNA expression profile in a dataset of 31 matched pairs for which both 
miRNA extracted from PBMCs and plasma. Due to the violation of paired t-test assumptions, a Wilcoxon 
matched-pairs signed-ranks test was applied. The median and the IQR (interquartile range) of the differences 
of miR expression within each set are provided for descriptive purpose. 
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4.7 Expression analysis on PBMCs and plasma samples from drug-naïve PD 
patients and unaffected matched controls. 
Since all previously analyzed samples PD patients were undergoing L-dopa 
therapy, the observed difference in miRNA expression could be the consequence 
of the L-dopa treatment. So, in order to investigate if the observed difference in 
miRNA expression could be the consequence of L-dopa treatment rather than to 
the PD pathogenesis per se, we performed an expression analysis on PBMCs and 
plasma samples from drug-naïve PD patients and unaffected matched control. 
 
4.7.1  MiRNAs expression analysis in PBMCs samples from drug-naїve PD 
patients and unaffected matched controls 
 
The ad hoc-power calculation (the sample size needed to have the same 
difference in miRNAs expression between blood drug-naïve PD samples and 
controls) evidenced that only 6 pairs of PBMCs/controls samples pair from drug-
naïve PD patients were needed to evaluate the expression of miR-103a-3p, and 
more then 23 for the others miRNAs (31 matched case-control pairs for miR-29a-
3p, 294 pairs for miR-29b-3p, 299 pairs for miR-30a-5p, and 26 pairs for miR-30b-
5p). In our study it was possible to enroll only 10 PBMCs samples from drug-naïve 
PD patients, with any possibility to enlarge the sample size. 
Based on this and on the available number of drug-naïve PD patients, it was 
performed a first exploratory expression analysis only for miR-103a-3p, and no 
significant difference could be detected.  
 
Although the sample size calculation demonstrated that there was not enough 
power to detect significant changes in expression for miR-29a-3p, miR-29b-3p, 
miR-30a-5p, and miR-30b-5p in 10 PBMCs samples from drug-naïve PD patients, 
we decided anyhow to evaluate their expression. It could be still argued that effect 
size estimated, used to calculate the sample size, came indeed from a different 
population, the group of PBMCs L-dopa treated PD patients. Hence, the  
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magnitude of the effects observed in the treated patients versus controls might not 
be totally comparable with the magnitude of the effects in the drug-naïve PD 
patients. From this different perspective, it becomes interesting to evaluate the 
expression of all miRNAs in the PBMCs drug-naïve PD group versus unaffected 
matched controls, even if the numbers were low and with no possibility to collect 
additional PBMCs samples from drug-naïve PD patients into the study.  
 
The expression analysis indicated no significant differential expression, as shown 
in Table 7. Due to the very likely lack of power, these results are not conclusive 
since it cannot be ruled out that a small, but statistically and possibly clinically 
significant difference in miRNAs expression would be detected in a larger sample 
size. 
miRNA N pairs=10 P-value Wilcoxon  
miR-29a-3p 0.611* 
miR-29b-3p 0.182* 
miR-30a-5p 0.699* 
miR-30b-5p 0.315* 
miR-103-3p 0.785 
Table 7. Results of miRNAs expression analysis in 10 PBMCs samples from drug-naïve PD patients 
and matched controls. Due to the small sample size a Wilcoxon matched-pairs signed-ranks test was 
applied. *underpowered sample. 
 
4.7.2  MiRNAs expression analysis in plasma samples from drug-naїve PD 
patients and unaffected matched controls 
 
The exploratory expression analysis was performed on 10 plasma samples from 
drug-naïve PD patients and their matched disease-free controls deriving from the 
same individuals of the previously analyzed 10 PBMCs samples from drug-naïve 
PD group. 
The expression analysis has showed an interesting trend of higher expression of 
miR-30b-5p (p=0.0858) compared to healthy controls, whereas the trend of the  
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miR-30a-5p observed in the 50 plasma samples from L-dopa treated PD patients, 
has been lost (Table 8).  
miRNA  N pairs = 50 
P value                              
paired t-test 
miRNA  N pairs = 10 P-value Wilcoxon 
miR-29a-3p 0.5118 miR-29a-3p 0.3139 
miR-29b-3p Not found in plasma miR-29b-3p Not found in plasma 
miR-30a-5p 0.054 miR-30a-5p 0.2135 
miR-30b-5p 0.6781 miR-30b-5p 0.0858 
miR-103a-3p 0.5927 miR-103-3p 0.2135 
Table 8. Comparison of the expression analysis of miRNAs in 10 plasma samples from drug-naïve PD 
patients and 50 plasma samples from L-dopa treated PD patients and their matched controls. Due to 
the small sample size a Wilcoxon matched-pairs signed-ranks test is applied for the 10 drug- naïve PD 
samples. 
 
4.8 Preliminary statistical analysis suggested miRNAs over-expression trend 
according to the gender. 
Very preliminary results of the subgroup analysis in PBMCs and plasma, stratifying 
the samples by the gender, suggest that there is a trend of differentially miRNA 
expression according to the gender. In particular, miR-29a-3p displays a 
borderline significance trend in females only, while there is a trend of significance 
for miR-30a-5p in males only (data not shown). However, due to the small gender 
groups available, these results have only an exploratory role and should be 
investigated in a larger sample set, allowing testing for the statistical interaction 
between gender and miRNAs expression. 
 
4.9 Exploratory deep sequencing on PBMCs samples from L-dopa treated PD 
patients and unaffected matched controls. 
In order to identify more PD miRNA candidates, we decided to perform miRNA 
profiling in PBMCs samples from L-dopa treated PD patients versus unaffected 
matched controls using a Next Generation Sequencing approach. The Illumina 
MiSeq NGS system was acquired as new platform.  
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The first step, needed to settle and standardized the NGS analysis methods, was 
to create cleaned libraries and to have an adequate number of total reads as 
sequencing output. The final idea was to compare the gold-standard qRT-PCR 
miRNAs results with the bioinformatics sequencing data analysis. 
 
The experiment consisted in two critical steps: the library preparation for the 
sequencing data generation and the bioinformatics analysis of the NGS data 
output.  
Regarding the library preparation, the critical issue was to obtain a final cleaned 
miRNAs library to load on the NGS system, starting from a low amount of total 
RNA.  
Regarding the bioinformatics analysis, it was established an in-house 
bioinformatics analysis pipeline and it was compared to miRDeep2. MiRDeep2 is 
one of the most common analysis tool used for alignment and read count 
generation; it is based on the miRNA biogenesis model, the ability to predict a 
miRNA’s existence by detection of mature miRNA or any one of its precursor or 
stem loop sequences. Moreover it is able to predict novel miRNAs based on the 
alignment of the putative miRNA to the genome (Metpally et al., 2013). Despite the 
differences in procedures of the in-house pipeline and miRDeep2, the results of 
both pipelines were quite similar. Differential expression analysis of miRNA read 
counts identified by miRDeep2 was performed using two different analysis 
packages designed to work with RNA based read count data, called DESeq2 and 
EdgeR (Metpally et al., 2013). These two different analysis packages are used 
normally to detect significant, differentially expressed miRNAs.  
 
Despite the difference in procedures of the in-house pipeline and miRDeep2, the 
results of both pipelines were quite similar, namely no known small RNAs were 
found to be differentially expressed. Moreover, the bioinformatics sequencing 
analysis for both pipelines resulted in an opposite direction of miRNA expression 
in comparison to the qRT-PCR expression analysis (Figure 3). Expression 
analysis of miR-103a-3p in PBMCs samples from L-dopa treated PD patients and  
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unaffected matched controls, showed the highest overlapping rate between the 
sequencing and the expression results  
 
 
Figure 3. MiRNAS sequencing and qRT-PCR analysis results. Comparison of folds changes (FC) between 
sequence. 
As consequence of these results, a saturation curve was done in order to estimate 
the number of reads needed to have depth enough to be able to identify miRNA 
deregulation and unfortunately the number of reads generated was not sufficient 
(Table 9). Further experiments will be carried out to expand the sample number 
and obtain around 5 million miRNA reads per sample. To conclude, despite the 
number of reads generated and the number of samples sequenced in this pilot 
phase, were not sufficient to generate sequencing results in a meaningful 
biological analysis and solid statistics. 
 
 
 
 
 
 
Page | 40  
 
Results
 
 
MiSeq run Number reads (milion) % reads mapped to miRNA 
1 13.5 17 
2 15.8 35 
3 1.74 10 
Table 9. Number of total reads generated in three indipendent miRNA sequencing runs each for four 
samples. 
 
4.10 Sophisticated in silico approach predicts reliable and promising 
putative target genes. 
MiRNAs regulate simultaneously several different target genes, therefore even 
small differences in miRNA expression can potentially cause relevant biological 
effects (Ma et al., 2012). For this reason, in order to better understand the 
underlying biology and the role of the up-regulation of miR-29a-3p, miR-30b-5p, 
and 103a-3p in PBMCs samples from L-dopa treated PD patients and the up-
regulation trend of miR-30a-5p in plasma samples from L-dopa treated PD 
patients, it was elaborated a more sophisticated in silico approach. We applied a 
computational approach for the identification and prioritization of candidate targets. 
Candidate targets were prioritized based on annotation and predictions from 
different miRNA target databases combined with different types of evidence 
relating candidates to PD genes and processes (Figure 4). For each deregulated 
miRNA, the results of the 20 top ranking candidates are reported in Table 10. Top 
ranking Endeavour prioritization candidates are also marked in the Table 10, 
providing additional evidence for relation with PD molecular mechanisms.  
 
The in silico analysis revealed interesting putative target genes for miR-29a-3p, 
miR-30b-5p and miR103-3p, deregulated in PBMCs samples from L-dopa treated 
PD patients, related to PD and neurodegeneration, for example LRRK2 for 
miRNAs-30b-5p and miR-103a-3p, PARK7/DJ-1 for miRNA-29a-3p, and Bcl-2 as 
common target for miRNAs-30b-5p, miR-29a-3p, and miR-103a-3p. 
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The first exploratory target predictions for miR-30a-5p, deregulated in plasma 
samples from drug-naїve PD patients, has highlighted interesting putative targets, 
such as Bcl-2 protein.  
 
Table 10. MicroRNA target prioritization (Serafin et al., 2015). (A) miR-29a-3p target prioritization; (B) miR-
103a-3p target prioritization; (C) miR-30b-5p target prioritization; (D) miR-30a-5p target prioritization 
(A) miR-29a-3p target prioritization 
Rank 
GeneID 
HGNC 
Symbol 
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1 1281 COL3A1   3 3 3         
2 3479 IGF1 232  1 3 3  ● ●      
3 26959 HBP1   1 3 3         
4 2200 FBN1  399 2 2 3     ●    
5 7837 PXDN 240  1 3 3  ● ●      
6 207 AKT1 6  1    ● ● ● ●   17 
7 54454 ATAD2B 1592   3 3         
8 1287 COL4A5    3 3   ●      
9 2006 ELN   1 2 3   ●   ●   
10 11315 PARK7     1 ● ●  ● ● ●  1 
11 91404 SESTD1    3 2   ●      
12 2861 GPR37    3 2   ● ● ●   9 
13 596 BCL2 32 17 2    ● ● ●  ●   
14 6018 RLF    3 3    ● ●    
15 51050 PI15    3 3         
16 998 CDC42  159 2 1 2  ●  ● ●    
17 55048 VPS37C    3 3   ●  ●    
18 84206 MEX3B 7   2 3   ● ●     
19 2597 GAPDH 28  1    ●  ● ●  ● 8 
20 5728 PTEN 851 190 2 2 3   ● ●    14 
Rank: candidate rank according to CRscore. Rank miR-30b-5p, Rank miR-103a-3p = Rank in miR-30b-5p and 
miR-103a-3p target lists respectively. V_PMID = Number of distinct PubMed identifiers reporting candidate as 
miRNA target in validated target resources. #PF, #PP = PF scores above cutoff according to target prediction 
databases with full and incomplete identifiers respectively. InSet_AVPD = Candidates included in panel set 
AVPD are marked with . GOSlim = Candidate genes are marked if their annotation matches GO terms in 
GOPD panel or any of their children. BPscore = Candidate gene is marked if functionally related (BPScore >= 
0.8) to genes in AVPD or CPD sets. PPI, Cpx = Candidate gene is marked if their encoded protein is reported  
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to interact with proteins from AVPD or CPD sets or form a complex with AVPD or CPD proteins. 
Mitochondrion, ParkinTAP = Candidate gene is marked if included in Mito set with Mitochondrion related 
proteins and in set ParkinTAP obtained from a Parkin interaction screen, respectively. Endeavour100 = 
Candidate rank within Endeavour top 100. COL3A1= collagen, type III, alpha 1; IGF1= insulin-like growth 
factor 1; HBP1= HMG-box transcription factor 1; FBN1 = fibrillin 1; PXDN= peroxidasin homolog (Drosophila); 
AKT1 = v-akt murine thymoma viral oncogene homolog 1; ATAD2B = ATPase family, AAA domain containing 
2B; COL4A5 = collagen, type IV, alpha 5; ELN= elastin; PARK7= parkinson protein 7; SESTD1 = SEC14 and 
spectrin domains 1; GPR37 = G protein-coupled receptor 37; BCL2 = Bcell CLL/lymphoma 2; RLF = 
rearranged L-myc fusion; PI15 = peptidase inhibitor 15; CDC42 = cell division cycle 42; VPS37C = vacuolar 
protein sorting 37 homolog C (S. cerevisiae); MEX3B = mex-3 RNA binding family member B; GAPDH = 
glyceraldehyde-3-phosphate dehydrogenase; PTEN= phosphatase and tensin homolog (Serafin et al., 2015). 
 
(B) miR-103a-3p target prioritization 
Rank 
GeneID HGNC Symbol 
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1 23405 DICER1 150 761 2 3 3         
2 4763 NF1  854 1 3 3  ●      26 
3 9683 N4BP1 692  1 3 3   ●      
4 2247 FGF2  451 1 3 2   ●      
5 63982 ANO3    3 3         
6 1983 EIF5    3 3   ● ● ●   1 
7 8313 AXIN2   1 3 3   ●      
8 3267 AGFG1   1 3 2     ●    
9 7533 YWHAH   1 2 2  ●  ● ●   72 
10 11244 ZHX1   1 3 2         
11 93 ACVR2B   1 2 2   ●      
12 8573 CASK    3 1   ● ●    13 
13 9441 MED26 1050   3 3         
14 120892 LRRK2  16   1 ● ●  ●  ●  3 
15 25777 SUN2   1 2 3     ●    
16 23710 GABARAPL1   1    ●  ● ●    
17 596 BCL2 13 32 1    ● ● ●  ●   
18 81565 NDEL1  283 1 3 3   ●      
19 1021 CDK6 26  2 2 1   ● ●    60 
20 3181 HNRNPA2B1  191 1 2 2     ●  ●  
 
See column description in Table 10 (A). DICER1 = dicer 1, ribonuclease type III; NF1 = neurofibromin 1; 
N4BP1 = NEDD4 binding protein 1; FGF2 = fibroblast growth factor 2 (basic); ANO3 = anoctamin 3; EIF5 = 
eukaryotic translation initiation factor 5; AXIN2 = axin 2; AGFG1= ArfGAP with FG repeats 1; YWHAH = 
tyrosine 3- monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide; ZHX1 = zinc 
fingers and homeoboxes 1; ACVR2B = activin A receptor, type IIB; CASK = calcium/calmodulin-dependent  
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serine protein kinase (MAGUK family); MED26 = mediator complex subunit 26; LRRK2: leucine-rich repeat 
kinase 2; SUN2 = Sad1 and UNC84 domain containing 2; GABARAPL1 = GABA(A) receptorassociated 
protein like 1; BCL2 = B-cell CLL/lymphoma 2; NDEL1= nudE neurodevelopment protein 1-like 1; CDK6 = 
cyclin-dependent kinase 6, HNRNPA2B1 = heterogeneous nuclear ribonucleoprotein A2/B1 (Serafin et al., 
2015). 
 
(C) miR-30b-3p target prioritization 
Rank                                              GeneID
HGNC 
Symbol 
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1 6622 SNCA   1   ● ● ● ●  ●   1 
2 860 RUNX2 1560  2 3 3          
3 4734 NEDD4   1 2 2   ● ● ●     
4 27327 TNRC6A  1849  3 3          
5 255520 ELMOD2   1 2 3   ●    ●   
6 207 AKT1 6  1    ● ● ● ●    24 
7 84206 MEX3B 18   3 3   ● ●      
8 27252 KLHL20    3 3     ●     
9 166968 MIER3   1 3 2          
10 8726 EED 1789  1 3 3          
11 4907 NT5E   1 3 3          
12 84002 B3GNT5 1380  1 3 3          
13 57551 TAOK1  820 1 3 2   ●       
14 9140 ATG12   1 3 2  ●        
15 51809 GALNT7  425 2 2 3          
16 120892 LRRK2  14  1 1 ● ●  ●  ●   3 
17 57763 ANKRA2    3 3          
18 5305 PIP4K2A   1 2 2   ●       
19 8878 SQSTM1   1    ● ● ● ●  ● ● 12 
20 92140 MTDH    3 2  ●        
See column description in Table 10 (A) ; Rank miR-29a-3p, Rank miR-103a-3p = Rank in miR-29a-3p and 
miR-103a-3p target lists respectively. ParkinUBQ = Candidates marked with are included in set ParkinUBQ 
consisting of Parkin dependent ubiquitylation targets. ParkinInt = Candidates marked with are included in set 
ParkinInt obtained from a Parkin interaction screen. SNCA = synuclein, alpha (non A4 component of amyloid 
precursor); RUNX2 = runt-related transcription factor 2; NEDD4 = neural precursor cell expressed, 
developmentally down-regulated 4, E3 ubiquitin protein ligase; TNRC6A = trinucleotide repeat containing 6A; 
ELMOD2 = ELMO/CED-12 domain containing 2; AKT1 = v-akt murine thymoma viral oncogene homolog 1; 
MEX3B = mex-3 RNA binding family member B; KLHL20 = kelch-like family member 20; MIER3 = mesoderm  
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induction early response 1, family member 3; EED = embryonic ectoderm development; NT5E = 5'-
nucleotidase, ecto (CD73); B3GNT5 = UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5; 
TAOK1 = TAO kinase 1; ATG12 = autophagy related 12; GALNT7 = UDP-N-acetylalpha- D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc- T7); LRRK2 = leucine-rich repeat 
kinase 2; ANKRA2= ankyrin repeat, family A (RFXANK-like) 2; PIP4K2A = phosphatidylinositol-5-phosphate 4-
kinase, type II, alpha; SQSTM1 = sequestosome 1; MTDH = metadherin (Serafin et al., 2015). 
 
(D) miR-30a-5p target prioritization 
Rank GeneID 
HGNC 
Symbol 
mTB TB DIA PD GO PPI Cpx Reac FSBP FSMF 
1 207 AKT1   1     8 5 1   8 2 
2 1956 EGFR W 5       4   1 5 3 
3 25 ABL1 F 1 0.97   5 4     4 4 
4 120892 LRRK2     0.86 Val 12 4 2   3 4 
5 5594 MAPK1 W 3       2 2 1 5 2 
6 351 APP   1     2 7 2 1 1 2 
7 11315 PARK7   1   Val 15 3 2   2 6 
8 10273 STUB1 W 2       5 4 1 1 2 
9 581 BAX W 6     18 2     1 1 
10 57099 AVEN F 2 0.97           9 22 
11 8301 PICALM W 7 0.99   1 1 1 2 2 1 
12 598 BCL2L1 W 4     9 3     2 5 
13 1499 CTNNB1 W 6     1 2     5 1 
14 596 BCL2     0.77   17 2     5   
15 3320 HSP90AA1   1     3 7 4     1 
16 8678 BECN1 F 2 0.86   9 1     2   
17 26986 PABPC1 W 2       2 4 1 1 2 
18 7157 TP53   2     14 2 1   2   
19 27303 RBMS3 W 5             9   
20 7534 YWHAZ W 7 0.83   1 3 3     3 
HGNC: HUGO Gene Nomenclature Committee gene symbol; GeneID: Entrez Gene identifier; mTB: 
miRTarBase database v4.5. W: weak funtional interaction (e.g. proteomics study), F: functional interaction 
(e.g. luciferase reporter assay, qRT-PCR, Western blot); TB: TarBase database v7. Number of gene records 
in miRNA results. DIA: DIANA microT database v5 miTG score; PD: Overlap with PD gene panel. Val: 
ValidatedPD; GO: Overlap with PD GO panel. Number of GO terms annotated to miRBA target gene that are 
descending from a panel term; PPI, Cpx, Reac: Number of proteins from PD gene panel co-annotated with a 
direct PPI in iRefIndex v14 (PPI), in the same protein complex in iRefIndex v14, in the same reaction step in 
Reactome v52. FSBP, FSMF: Number of proteins from PD gene panel that have similar Gene Ontology 
annotations using GO release 2015.07 and biological process (FSBP) or molecular function (FSMF) ontology.  
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AKT1 [PDB:P31749], EGFR [PDB:P00533], ABL1 [PDB:P00519], LRRK2 [PDB:Q17RV3], MAPK1 
[PDB:P28482], APP [PDB:P05067], PARK7 (DJ-1) [PDB:Q99497], STUB1 [PDB: Q9UNE7], BAX [PDB: 
Q07812], AVEN [PDB: Q9NQS1], PICALM [PDB: Q13492], CTNNB1 [PDB: P35222], BCL2L1 [PDB: Q07817], 
BCL2 [PDB: P10415], HSP90AA1 [PDB: P07900], BECN1 [PDB: Q14457], PABPC1 [PDB: P11940], TP53 
[PDB:P04637], RBMS3 [PDB: Q6XE24], YWHAZ [PDB: P63104]. 
 
 
 
 
Figure 4. Prioritization of miRNA target candidates. Prioritization of miRNA target candidates based on 
annotation from multiple miRNA target resources and different types of evidence relating them to PD genes 
and processes. Candidate genes are represented by different geometric shapes, they are scored according to 
the different types of evidence (center), which are used to compute a combined rank (right) (Serafin et al., 
2015). 
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5. DISCUSSION 
 
MicroRNAs are small non-coding RNAs of 20-22 nucleotides involved in 
transcriptional and post-transcriptional regulation of gene expression. MiRNAs 
function via base-pairing with complementary sequences within target mRNA 
molecules, usually resulting in gene silencing via translational repression or target 
degradation. MiRNAs are involved in several physiological functions, and several 
studies have demonstrated abnormal expression levels of miRNAs in different 
pathologies, including Parkinson’s disease. Biomarkers from easy accessible 
resources, such as peripheral blood, plasma, serum, urine, saliva, and 
cerebrospinal fluid could be used to detect and monitor the disease much earlier, 
even before symptoms appear. For this study we decided to consider peripheral 
blood and plasma as potential diagnostic sources as they are readily obtainable 
and reflect dynamically a system-wide biology.  
The work of the present study revealed for the first time an over-expression of 
miR-103a-3p and an up-regulation of miR-30b-5p and miR-29a-3p in PBMCs 
samples from L-dopa treated PD patients. On the contrary was observed a trend 
of higher expression of miR-30a-5p in plasma samples from L-dopa treated PD 
patients and of miR-30b-5p in plasma samples from drug-naїve PD group. 
Moreover, using bioinformatics tools, candidate target genes for each blood and 
plasma deregulated miRNA have been identified and prioritized. 
 
5.1 Importance of the miRNAs expression data normalization approach  
The importance of the miRNAs expression data normalization is currently broadly 
recognized. The normalization process consist in the comparison of the 
expression levels of the investigated miRNAs (case-control groups) with the 
expression of one or more endogenous reference gene/s in order to obtain a 
relative quantification of the investigated miRNAs (Wotschofsky et al., 2011). The 
expression of an ideal reference gene should not vary in the tissues or cells under 
investigation, in response to treatment or in presence of pathology (Sanders et al., 
2012). It is recognized that combining different reference genes for normalization 
can avoid misleading estimation of the expression analysis data, which could arise  
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if only a single or improper reference genes is used (Vandesompele et al., 2002) 
and for that reason it is important to use at least 2 reference genes.  
The factors that can affect the efficiency of endogenous reference genes chosen 
as normalizers, could be technical factors including variability during the sample 
collection and processing, as well the presence in body fluids of various factors 
affecting miRNAs purification and qRT-PCR analysis. At the moment different 
normalization approaches are described in literature, but at the same time no 
single standard normalization method is commonly accepted. 
Indeed, it has been shown in several publications that traditional reference genes 
used in qRT-PCR studies do not always show a stable expression pattern, 
because the same gene revealed as almost invariant for certain tissues or cell 
types, could present highly variable expression levels in other tissues or 
experimental conditions (Margis et al., 2011; Burgos et al., 2014). Thus, suitable 
control genes are extremely specific for particular sample sets and experimental 
models, being a crucial component in assessing gene expression patterns with 
confidence. 
 
To date, has not been defined an established and standardized reliable reference 
gene set for miRNA profiling analysis by qRT-PCR in peripheral blood samples 
from PD patients. We performed a pilot study using GeNorm and NormFinder 
algorithms to identify, among several candidate reference genes (RNU24, Z30, 
RNU6B and miR-103a-3p), a reliable set of normalizers for expression analysis in 
PBMCs samples from L-dopa treated PD patients. The selection of the candidate 
endogenous reference genes was based on the literature (Margis et al., 2011; 
Martins et al., 2011) and we identified RNU24 and Z30 as the best stably 
endogenous reference genes set to use in PBMCs L-dopa treated PD expression 
study. Although Martins and collaborators (Martins et al., PLOS one, 2011) used 
miR-103a-3p in their study as reference gene, in our dataset miR-103a-3p alone 
or in combination with the other reference genes reverses the expression 
directions of miR-29a-3p and miR-30b-5p. Our results are consistent with the 
available literature evidence, which may have suggested a priori, the unsuitability 
of miR-103a-3p as reference gene in a PD study, as miRNA-103a-3p is a member  
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of the miR-15/107 group, involved in several physiological functions and 
pathologies, including neurodegenerative diseases. Indeed, miR-103a-3p is 
involved in PD targeting human CDK5R1 (Cyclin-dependent kinase 5, regulatory 
subunit 1), (Moncini et al., 2011) and the requirement of CDK5 is the major signal 
in neuronal death pathways in vivo (Smith PD et al., 2003), and it is involved in 
other neurodegenerative diseases, such as Alzheimer disease (Wang G et al., 
2008).  
 
For the expression analysis in plasma, we selected from the literature miR-191-5p 
as putative candidate endogenous reference gene (Cardo et al., 2012; 
Geekiyanage et al., 2011) and three exogenous oligos spike-in miRNAs (cel-miR-
39-3p, cel-miR-54-3p and cel-miR-238-3p) (Kang et al., 2012). As miR-191-5p, 
used by Cardo and collaborators as endogenous control, showed in our data high 
expression variability, we excluded it as reference gene and decided to normalize 
our expression data exclusively against the three spike-in miRNAs. Because of the 
lack of established reference genes (Kang et al., 2012), even if oligos spike-in are 
almost exclusively used to monitor RNA purification and retrotranscription 
efficiencies, is not rare to find them in several miRNAs expression studies in 
serum or plasma as normalizers (Mitchell et al., 2008; Brase et al., 2011). 
 
Our study demonstrated the complexity of the choice of a suitable reference gene 
set. The differences in relative expression of the selected microRNAs between 
PBMCs samples from L-dopa treated PD patients and unaffected controls were 
profoundly affected by the choice of reference gene set, and in some cases can 
completely reverse the direction of miRNAs expression. The results highlight the 
importance of a careful choice of a stable reference genes set, which should be 
evaluated depending on the specific on-going study, not relying solely on 
published data. 
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5.2 Over-expression of miR-29a-3p and miR-30b-5p in PBMC samples from L-
dopa treated PD patients 
The expression analysis on PBMCs samples from L-dopa treated PD patients and 
unaffected matched controls, showed an over-expression of miR-29a-3p and miR-
30b-5p. These finding was unexpected, since in previous papers miR-29a-3p and 
miR-30b-5p were showed down-regulated by Margis (Margis et al., 2011) and 
Martins (Martins et al., 2011) studies, respectively. This discordant result can be 
explained by the use of PD sample sets with different size and clinical features, 
and by differences in the pharmacological treatment. Moreover, the discordant 
results could be explained by distinct experimental conditions, including RNA 
purification, expression analysis methods, and the selection of reference genes 
used as normalizer, because a misleading estimation of the expression analysis 
data can arise if only a single or improper reference genes are used 
(Vandesompele et al., 2002). 
For our qRT-PCR analyses we used a matched case-control experimental design 
on 36 PBMCs samples from L-dopa treated PD patients and unaffected matched 
controls, whereas Margis (Margis et al., 2011) and Martins (Martins et al., 2011) 
followed an unmatched study design.  
Margis and collaborators analyzed extremely small sample sets. They showed a 
significant down-regulation of miR-29a-3p in PBMCs samples from 8 drug-naïve 
PD patients by qRT-PCR and only a trend to lower expression in 4 L-
dopa/Carbidoba treated PD patients, whereas no difference in expression was 
observed for the 7 early onset PD patients. Furthermore, no data are available 
regarding the reference genes used in their qRT-PCR study, and the selection of 
the normalizer could be one of the reasons of the different direction in miRNAs 
expression. 
Martins and collaborators profiled by microarray assays 19 PD patients and 13 
controls and they found a down-regulation of miR-30b-5p in PD patients. To 
validate their microarray results, they performed an expression analysis on a 
subset of five miRNAs, unfortunately not including miR-30b-5p. The five 
deregulated miRNAs were validated by Martins and collaborators using miR-103a- 
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3p as normalizer. In our study miR-103-3p has been identified as unsuitable 
reference gene as normalizer, as discussed above. 
 
5.3 Target prediction priorization 
Our study demonstrated for the first time an over-expression of miR-103a-3p and 
a deregulation of miR-30b-5p and miR-29a-3p in PBMCs samples from L-dopa 
treated PD patients and unaffected controls, and on the contrary it has been found 
a trend of higher expression of miR-30a-5p in the plasma samples from L-dopa 
treated PD patients. In order to better address further analyses and to understand 
the underlying biology and the role of the observed miRNAs up-regulation, we 
performed an in silico analysis of the three deregulated PBMCs miRNAs in L-dopa 
treated PD patients and an exploratory target prediction for the potentially up-
regulated plasma miRNA in L-dopa treated PD patients. Even if we observed only 
a trend towards significance for up-regulation of miR-30a-5p in plasma samples 
from L-dopa treated PD patients, investigating its potential biological context was 
anyway interesting even becuase it was found up-regulated in serum post-mortem 
samples from PD patients by Burgos and collaborators (Burgos et al., 2014).  
 
The in silico analysis, used to prioritize putative targets of the deregulated 
miRNAs, has identified putative candidate target genes, including genes related to 
neurodegeneration and PD. In this chapter we want to focus on Bcl-2, protein 
involved in apoptosis and mithocondrial dysfunction, as common predicted target 
for all up-regulated miRNAs (miR-30b-5p, miR-29a-3p, miR-103a-3p in PBMCs, 
and miR-30a-5p in plasma) and the putative involvement of miR-103a-3p in the 
insulin resistance process, even if its precise role remains still to be defined. 
 
5.3.1 Bcl-2 as putative common target for all up-regulated miRNAs in 
PBMCs and plasma samples from L-dopa treated PD patients 
The in silico analyses of all over-expressed microRNAs suggest as common 
target, the anti-apoptotic protein Bcl-2, belonging to a family involved in the  
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regulation of mitochondrial dynamics and apoptosis. To date, the knowledge 
related to the function of Bcl-2 family proteins, supports the idea of their 
involvement in neuronal death in different models of PD, albeit it has not yet been 
clarified in detail the role and mechanism of action of each of them. 
 
On a physiological level in cells there must always be a homeostatic balance 
between proliferation and apoptosis, because excessive cell death can lead to 
neurodegenerative disease and on the contrary, excessive cell survival function 
could lead to autoimmune diseases or cancer. Indeed, the ratio between these two 
conditions helps to determine in part, the susceptibility of cells to a death 
promoting signal. The apoptotic process can occur through two different activation 
pathways: the extrinsic pathway mediated by the activation of pro-caspases and 
cell death receptors, and the intrinsic or mitochondrial pathway, regulated by the 
Bcl-2 family (Brunelle and Letai, 2009), focus of our discussion. 
The sensitivity of cells to apoptotic stimuli can depend on the balance of pro- and 
anti-apoptotic Bcl-2 family member’s activity. Bcl-2 protein is an integral 
membrane protein with an anti-apoptotic function, belonging to the family of 
proteins Bcl-2, localized in the outer mitochondrial membrane (MOM) and its 
function is to regulate the permeability of the MOM during the apoptosis (Brunelle 
and Letai, 2009). Normally Bcl-2 anti-apoptotic family members, including the Bcl-
2 protein, modulate the pro-apoptotic Bax and Bak proteins by suppressing their 
activity, through inhibition of BH3-only proteins (Brunelle and Letai, 2009). We 
hypothesized that the over-expressed miRNAs could repress the expression of 
Bcl-2 anti-apoptotic proteins, resulting in an uncontrolled activation and homo-
oligomerization of Bax and Bak. The consequent homo-oligomerization of the pro-
apoptotic proteins Bax and Bak, results in the formation of pores (MAC, 
mitochondrial apoptosis-induced channel) at the level of the MOM. The formation 
of these pores, increases the permeability of the mitochondrion, and reduces in 
part the ability of the cell to control the passage of water and ions, resulting in the 
release into the cytosol of pro-apoptotic factors including cytochrome c and SMAC 
(Second Mithocondria-derived Activator of Caspases) (Lindsay et al., 2010). 
SMAC binds to inhibitor of apoptosis (IAPS) inhibiting its function, while the  
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cytochrome c binds to Apaf1 and ATP generating a protein complex, called 
apoptosome, which aggregates and activates pro-caspase 9, inducing apoptosis 
(Lindsay et al., 2010). 
The hypothesis to be confirmed through target functional analysis is that the over-
expressed miRNAs inhibit the activity of the protein Bcl-2 by eliminating its anti-
apoptotic activity in response to many varieties of insult and failing in preventing 
the activation and homo-oligomerization of both Bax and Bak. 
 
 
Mitochondrial and death receptor-mediated pathway to apoptosis. (Czabotar et al., 2014). 
 
Understanding the mechanism of action of microRNAs linked to Bcl-2 family 
proteins in PD, could clarify the intracellular mechanisms leading to neuronal 
death and may also provide a rationale in using them as biomarkers. 
Interesting, Rasagiline is a selective and irreversible inhibitor of MOA-B 
(Monoamine oxidase B), and can be used as monotherapy or as adjunctive  
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therapy to L-dopa treatment in patients with fluctuations end-dose interval of time 
between the administrations of L-dopa (Weinreb et al., 2006). Fluctuations happen 
when the effects of the L-dopa treatment are exhausted and the symptoms recur. 
These symptoms are related to a reduction of the effects of L-dopa and the patient 
suddenly changes from the state "on", in which he is able to move, to the "off", 
state of immobility. Weinreb and colleagues (Weinreb et al., 2006) showed a 
potential neuroprotective effect of Rasagiline, up-regulating the expression of anti-
apoptotic proteins, such as Bcl-2, Bcl-xL and Bcl-w. 
 
5.3.2 Insulin resistance and over-expression of miR-103a-3p 
Several recent discoveries have highlighted common cellular pathways that 
potentially relate neurodegenerative processes with abnormal mitochondrial 
function and abnormal glucose metabolism. 
MiR-103a-3p has documented relationships to insulin resistance, a process 
possibly linked also to neurodegeneration in PD, whereas miR-30a-5p plays a 
central role in the mitochondrial fission process and indirectly to the insulin 
secretion. 
 
In a recent study (Trajkovski et al., 2011) it was shown in mouse model as miR-
103 is related to insulin-metabolism. The connection between miR-103 and insulin 
is relevant, since insulin is known to regulate dopamine release. Moreover in a 
recent study a correlation between PD and a hyperglycaemic status was shown in 
rats (Herrera et al., 2010). 
Neuropathological studies of patients with Parkinson’s disease have shown that 
insulin receptors are densely represented on the dopaminergic neurons of the 
substantia nigra pars compacta, and loss of insulin receptor immunoreactivity and 
messenger RNA in the substantia nigra pars compacta of patients with 
Parkinson’s disease coincides with loss of tyrosine hydroxylase messenger RNA 
(the rate-limiting enzyme in dopamine synthesis) (Aviles-Olmos et al., 2013). 
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Animal and in vitro studies have suggested a role for insulin in regulation of brain 
dopaminergic activity featuring a reciprocal regulation between the two chemicals 
(Craft and Watson, 2004).  
 
Pancreas secretes two important hormones involved in regulation of glucose 
metabolism, lipids and proteins. First, glucagon which acts to increase the glucose 
in blood through degradation of glycogen into glucose and it is release in blood. 
Second, insulin that acts to decrease the blood glucose through its uptake by 
adipocytes and muscles and to increase the activity of glycogen synthase in the 
liver. The plasma glucose concentration reflects the balance between the 
absorption from the gastrointestinal tract, the usage at tissue level and the 
endogenous production. The hormone insulin and several insulin-like growth 
factors mainly control the glucose homeostasis. 
The insulin resistance condition results in an uncontrolled release of glucose in the 
blood and a reduced response of cellular insulin receptors to insulin. Pancreas 
tries to compensate the reduced sensitivity of cells to insulin by increasing its 
synthesis and its release. 
The first evidence of a relationship between PD and insulin resistance is linked to 
the early 70s. Van Woert and Mueller (Van Woert and Mueller, 1971) showed that 
drug-naїve PD patients presented reduced insulin-mediated glucose uptake, and 
Boyd (Boyd et al. 1971) identified an inhibition of early insulin secretion and long-
term hyperinsulinemia and hyperglycemia after glucose loading. In addition, L-
dopa used since the 60s in the common PD treatment, can induce hyperglycemia 
and hyperinsulinemia (Aviles-Olmo et al., 2013). Different studies have reported 
high rates of glucose intolerance in PD patients and the effective hyperglycemic 
response to L-dopa and dopamine (Smith Y et al., 2012). They showed that L-
dopa treatment coupled with Carbidopa diminishes glycogen concentration, 
glycogen synthase activity, and insulin-stimulated glucose transport, suggesting 
that PD patients may have unrecognized insulin resistance. 
Although to date has not yet been demonstrated a direct in vivo regulatory action 
of miRNAs on insulin sensitivity, Trajkovski and colleagues (Trajkovski et al., 
2011) have shown that miR-103 and miR-107 are up-regulated in obese mice,  
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showing evidence of invovment of miRNAs in the regulation of insulin and in the 
process of insulin resistance. They have demonstrated that miR-103 and miR-107 
target caveolin-1, a critical regulator of the insulin receptor.  
Caveolin-1 is the main protein component of the caveolae, invaginations of the 
plasma membrane abundant in the insulin-dependent tissues, mainly adipose cells 
and muscle, and activates insulin signaling. The down-regulation of caveolin-1 
suppresses the expression of insulin receptor alpha and the insulin receptor 
substrate 1. Although the role of caveolin-1 is not still fully clear, its action may 
stabilize the insulin receptor at caveolae level. Caveolin-1 is inhibited as a result of 
high levels of expression of miR-103 and miR-107 in the adipocytes, destabilizing 
insulin receptors and inhibiting insulin-stimulated glucose uptake (Traijkovski et al., 
2011), acting as negative regulators of insulin sensitivity. The mechanism of action 
proposed suggests that miR-103 targets caveolin-1 reducing the number of insulin 
receptors in the caveolae and resulting in decreased downstream insulin signaling 
(Traijkovski et al., 2011).  
Our speculation is that, miR-103a-3p is over-expressed as consequence of L-dopa 
treatment in a negative feedback still unclear acting on caveolin-1 receptor, 
imparing insulin secretion and contributing to the insulin resistance. Obviously this 
idea has to be corroborated on the basis of further investigation with the aim to 
validate the predicted targets for miR-103a-3p in cell models. 
 
 
Interestingly, not only miR-103a-3p but also miR-30a-5p seems to be indirectly 
related to the insulin metabolism. Indeed, p53 has been identified as putative 
target gene for miR-30a-5p and validated by Li and colleagues (Li et al., 2010).  
There are evidences suggesting a regulation of mitochondrial fission by miR-30a-
5p through inhibition of p53, which causes a down-regulation in Drp1 levels 
(Dynamin-Related Protein-1) (Tanaka et al., 2008). Drp1 is a GTPase that causes 
scission of the mitochondrial outer membrane, resulting in mitochondrial 
fragmentation. A down-regulation of Drp1 causes both fission and autophagy 
inhibition (Li et al., 2010). The result of the inhibition of the fission process and a 
decreased mitochondrial autophagy is an accumulation of oxidized mitochondrial  
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proteins, reduced respiration and impaired insulin secretion (Twig et al., 2008). 
Therefore, in accordance to this evidence the up-regulation of miR-30a-5p in 
plasma drug-naїve PD samples might carry to over-regulation of p53 and Drp1, 
resulting in hyper secretion of insulin. 
 
 
The findings provided by our study and the data available in the current literature 
reveal the complexity of the biological context in which the deregulated miRNAs 
could act. This is not surprising taking into consideration that in general miRNAs 
exert their function by regulating several target genes, potentially involved in more 
than one single pathway. The hypotheses presented here require absolutely 
further investigations, but they highlight the impact that could have a confirmation 
of the deregulated miRNAs in PD regarding apoptosis and insulin resistance.  
Despite the preliminary character of the study, the results provide a rationale for 
validating the miRNAs diagnostic potential.  
 
5.4 The difference in miRNAs expression could be the consequence of L-
dopa treatment rather than to the PD pathogenesis per se? 
Our study demonstrated for the first time an over-expression of miR-103a-3p, and 
showed a deregulation of miR-30b-5p, and miR-29a-3p in PBMCs samples from L-
dopa treated PD patients, whereas no significant differential expression was 
detected in the PBMCs samples from drug-naïve PD patients sample set (Serafin 
et al., 2015).  
On the contrary, it has been found a trend of higher expression of miR-30b-5p in 
the plasma samples from drug-naïve PD patients and a trend of miR-30a-5p in the 
plasma samples from L-dopa treated PD patients. We can argue that the over-
expression trend of miR-30b-5p decrease until disappear in concomitance with the 
L-dopa drug treatment, and in parallel will appear an over-expression of miR-30a-
5p. Moreover, miR-29b-3p, normally expressed in PBMCs, was not detected in 
plasma samples from L-dopa treated PD patients.  
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The comparison between expressions profiles in PBMCs (Serafin et al., 2015) and 
plasma revealed clear differences for all analyzed miRNAs in L-dopa treated and 
drug-naïve PD/control pairs, indicating that different miRNA expression profiles are 
present in plasma and PBMCs samples from L-dopa treated PD patients and that 
L-dopa treatment might have an impact on the expression levels of miRNAs. 
 
In accordance to the PBMCs expression data, it can be hypothesized that the 
deregulation of the investigated miRNAs is due to the progression of the disease, 
resulting in miRNAs release from tissue into the circulation.  
On the other hand, in accordance to the plasma expression data, it cannot be 
excluded that the observed over-expression of miRNAs in plasma samples from L-
dopa treated PD patients could be the consequence of the L-dopa treatment.  
 
Only further investigations could confirm our preliminary data and validate the role 
of the deregulated miRNAs as putative biomarkers for PD.  
 
5.5 Plasma and blood as sources for PD biomarker 
The identification of specific biomarkers at early stages of the disease could lead 
to early patient's treatment, and during the progression of the disease a useful 
biomarker could help to monitor the secondary side effects in response to the L-
dopa treatment. A biomarker should meet requirements such as easy accessibility, 
high specificity and sensitivity, low costs and standard applicability in diagnostic 
laboratories. Biomarkers from easily accessible sources, such as peripheral blood, 
plasma/serum, saliva, urine, and cerebrospinal fluid could be used to detect and 
monitor PD in early stages, even before symptoms appear. 
 
For this study we decided to consider peripheral blood and plasma as potential 
diagnostic sources as they are readily obtainable and reflect dynamically a 
system-wide biology. Liew and colleagues (Liew et al., 2006) have compared 
genes expressed both in circulating blood cells and in different nine human 
tissues, finding approximately 80% of co-expressed genes and revealing that 
expression of 81.9% blood genes were shared by brain. This data suggest that  
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blood could act as sentinel of the disease, through an aberrant gene expression, 
reflecting changes within the cells occurring in association with injury or disease 
and as consequence of continuous interaction between blood and other body 
tissues.  
 
At the moment the precise mechanism of transport of brain tissue-specific miRNAs 
through the blood brain barrier (BBB) into the body circulation is still unknown. The 
BBB acts as checkpoint specialized to regulate the transport of nutrients and 
macromolecules and block the entry of viruses and bacteria (Cheng et al., 2013). 
However, some protein complexes can cross the BBB, suggesting that some 
tissue-specific disease biomarkers can be detected in body fluids.  
Circulating miRNAs are released in two different manners, the first one as result of 
cell lyses or apoptosis by passive leakage in pathological conditions, such as 
tissue damage, metastasis or inflammation. The other process, which still is not 
completely clear, is an active transport from the cells based on microvesicle-free 
miRNAs, associated with various multiprotein, such as Ago2 or lipoprotein 
complexes (HDL) or mediated by microvesicles (MVs) (e.g. microparticles and 
exosomes) or apoptotic bodies (ABs) (Grasso et al., 2014).  
As the cell-free miRNAs in body fluids are transported by exosomes or 
microvesicles, the suggested pathway indicates the transcytosis of the 
extracellular vesicles as the main actor to carry miRNAs from brain to body fluids. 
In that way the vesicles such as exosomes can cross the BBB endothelial cells by 
receptor-mediated endocytosis and release the exosomal contents into circulation. 
Montecalvo and colleagues (Montecalvo et al., 2012) showed that exosomes, 
carrying miRNAs, were secreted by dendtritic cells and that they could fuse with 
the target cell releasing their content. An effective trace of this mechanism is 
resulting by different studies showing that high abundant brain miRNAs were 
present in body fluids, such as plasma (Haqqani et al., 2013).  
 
Plasma samples showed a completely different miRNAs expression profile in 
comparison to peripheral blood samples, as discussed above. Thus, indicating that 
PBMCs and plasma are not interchangeable sources for miRNA biomarkers for  
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PD. The explanation of this discordance between blood and plasma miRNAs 
expression profile can be attributed to the different cell sources used for isolating 
miRNAs. 
Blood and plasma are both classifiable as optimal biomarkers sources, but each of 
them presents different advantages and disadvantages.  
It is widely believed that miRNAs are present mainly in plasma associated to 
vesicles, including exosomes, protein complexes (including non-vesicular 
lipoprotein complexes, non-vesicular RNA-binding proteins), and miRNA 
processing proteins, which may explain the different abundance levels of miRNAs, 
in fact, miRNAs isolated from PBMCs are more abundant, in comparison with 
miRNAs isolated from plasma. 
PBMCs share more than 80% miRNA of the transcriptome with brain (Liew et al., 
2006), but being living cells the miRNA expression can change after the sampling. 
This problem does not exist in plasma, once plasma has been isolated (after 
centrifugation of whole blood and separation of plasma), miRNA expression does 
not change anymore. This feature represents an important advantage in terms of 
biomarker measurements and laboratory procedures. 
An advantage to assess expression profiles using miRNAs isolated from plasma is 
the possibility to normalize variations during the recovery and amplification steps, 
using exogenous miRNAs as reference genes added to the plasma before the 
RNA extraction. Conversely, an advantage to use PBMCs for the miRNAs 
expression profiling is that they are therefore L-dopa responsive cells expressing, 
similarly to dopaminergic neurons, dopamine receptors and transporters. 
Moreover, miRNAs are much more abundant in PBMCs than in plasma. 
The other variables which can affect the miRNAs expression profile are due to 
variation and/or problems linked to the normal laboratory practice, such as the 
plasma/blood collection and processing. Plasma is the cell-free supernatant phase 
obtained after blood sample centrifugation. During this phase it is strictly 
recommended the use of suitable anticoagulants. Indeed, heparin inhibits the 
downstream PCR or sequencing reactions, whereas EDTA and citrate are 
acceptable anticoagulants. Moreover, during the aspiration and separation  
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procedures of the plasma there is a risk of contamination by cells from the buffy 
coat.  
 
It is always highly recommended to match cases and controls specimens in 
respect of many variables, which have not yet been carefully evaluated and that 
may be able to affect the study results, such as duration of freeze-storage of the 
sample, diurnal variation in miRNA levels (e.g. fasting vs non-fasting state), and 
white blood cell count (Kroh et al., 2010). It is known that some blood components 
could vary according to the fasting, but it is not clear if this status might be able to 
affect miRNAs levels in blood. MicroRNAs can be transported in the blood carried 
out by lipoproteins or vesicles, which may be affected by an individual's food 
intake (Moldovan et al., 2014) such as HDL particles whose concentration in the 
blood can vary during the day. In addition there may be improper recovery of 
miRNAs because of extraction methods influencing the expression profile. 
In conclusion, it is evident that, even being both peripheral blood and plasma good 
resources for biomarkers, it is important to carefully choose the tissue to analyse 
based on the specific on-going study and on the laboratory practice. 
 
5.6 Deep sequencing analysis: new insights. 
The Illumina MiSeq NGS platform was acquired as new platform, and the first 
approach in order to settle and standardized the NGS analysis methods, was 
comparing the gold-standard qRT-PCR miRNAs results previously done, with the 
bioinformatics sequencing data analysis. 
 
Despite the number of reads generated and the number of samples sequenced in 
this pilot phase, the performed saturation curve revealed that the number of reads 
needed to have enough coverage depth to identify miRNAs deregulation for our 
experiment was not sufficient. Also compared to other studies the number of total 
reads generated in our pilot experiments needed for an accurate miRNA 
expression analysis was low. For example, Dhahbi and collegues (Dhahbi et al., 
2011) obtained 9.1 to 11.4 million reads per sample, the group of Hu (Hu et al., 
2011) obtained 7.6 million reads per sample, and Morin (Morin et al., 2008)  
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obtained 6 million reads per sample. 
Regarding the sequencing and real time technologies, the data resulted in 
contrasting opposite miRNAs expression profiles. At this stage we were in for an 
interesting question, namely whether the NGS and qRT-PCR data could be 
directly compared. Unfortunately, there is no gold standard technique for 
measuring miRNA expression. Currently oligonucleotide microarray and 
quantitative real-time reverse-transcription PCR are two of the most common 
methods for evaluating known miRNAs. 
The analysis of the current literature stresses the need to compare the different 
expression results coming from the different platforms used for the expression 
analysis, such as microarray, NGS and qRT-PCR in terms of reproducibility, 
sensitivity, accuracy, and specificity.  
Some research groups found a good correlation between microarray, NGS and 
qRT-PCR for selected miRNAs, while others revealed conflicting data. 
Mestdagh and collaborators (Mestdagh et al., 2014) focused properly on that 
point. They selected a total of 66 miRNAs, found to be differentially expressed by 
at least one of the 12 most common commercially platforms. A comparison of 
small RNA sequencing, qRT-PCR and microarray, revealed that only two miRNAs 
(3%) were differentially expressed by all the platforms. Only 48% of the miRNAs 
were concordant for half of the analysed platforms. They pointed out the necessity 
to choose the appropriate analysis platform, because the choice could impact on 
the expression results. qRT-PCR platform remains the “gold standard” in terms of 
sensitivity and accuracy, analyzing samples with a low input RNA, having an 
overall better score, whereas sequencing platforms lose sensitivity for low-input-
amount RNAs differences (Mestdagh et al., 2014). Metpally and collaborators put 
in evidence that not only the choice of the platform depending on the study design 
is critical but also the selection of the analysis software packages used for data 
analysis (Metpally et al., 2013). They compared three common analysis tools used 
for alignment and read count generation named miRExpress, miRNAKey, and 
miRDeep2. Their study showed that miRDeep2 software has detected and aligned 
more miRNAs than miRExpressor and miRNAKey, and that miRExpress and 
miRNAKey have performed more similarly.  
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Another point to take in consideration and that can affect the sequencing analysis 
are the periodical changes in the miRBase database, used to design the arrays 
and qRT-PCR probes and to map the sequencing reads to known mature 
miRNAs. Indeed, the number of human miRNAs represented on an array 
depended mainly on the miRBase version at the time of array design. Moreover, 
the probe and primer design (qRT-PCR) can heavily influence the expression 
results. In conclusion, it is necessary to re-annotate microarray and qPCR probes 
prior to go on with the bioinformatics analysis (Git et al., 2010). 
Although qRT-PCR is considered the gold-standard and is used widely as a 
validation method for miRNA NGS and microarray data, there are various 
conflicting opinions regarding the reliability of qRT-PCR as validation method for 
NGS. Some evidences suggest the inadequacy of qRT-PCR as validation method 
for miRNA microarray (Git et al., 2010; Koshiol et al., 2010) and NGS data 
(Metpally et. al., 2013; Git et al., 2010). qRT-PCR do not detect small but 
significant variations of miRNAs sequences (Metpally et. al., 2013), probably 
because of the logarithmic nature of qRT-PCR, which may make difficult to detect 
modest changes in molecule number. It seems necessary to find some 
alternatives to qRT-PCR for microarray and sequencing validation data. 
 
 
To conclude, our analyses revealed an over-expression of miR-103-3p, miR29a-
3p, and miR-30b-5p in peripheral blood, and a trend of over-expression of miR-
30a-5p found in plasma of L-dopa treated PD patients. These miRNAs could act 
as diagnostic biomarkers specific for Parkinson’s disease or they could be a 
challenging resource as biomarkers monitoring the secondary side effects related 
to the drug therapy. Because of the side effects in L-dopa treatment it would be 
important to be able to monitor its levels in blood, so that an individual 
personalized therapy could be developed, and could be possible predict and avoid 
significant motor fluctuations. Indeed, each patient requires a different dosage of 
drug and the use of miRNAs as biomarker could represent an important variable 
for therapy improvement. 
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6. CONCLUSION 
 
Our study identified a set of reliable endogenous reference genes (RNU24 and 
Z30) to use in miRNAs expression studies on PBMcs samples in Parkinson's 
disease.  
We highlighted for the first time an over-expression of miR-103a-3p in PBMCs 
samples from L-dopa treated PD patients and unaffected matched controls and 
showed a deregulation of miR-29a-3p and miR-30b-5p from L-dopa treated PD 
patients and unaffected matched controls. No differences in miRNAs expression 
levels in PBMCs samples from drug-naïve PD patients were found. Further 
analysis in plasma samples from L-dopa treated PD patients indicated a trend of 
over-expression for miR-30a-5p and a trend of over-expression for miR-30b-5p in 
plasma samples from drug-naïve PD patients. Moreover, miR-29b-3p, previously 
found expressed in peripheral blood samples, is lost in plasma samples. This 
findings suggested that different miRNA expression profiles between PBMCs and 
plasma existed. Further analyses in patients before and after the beginning of the 
pharmacological therapy will be needed to define the involvement of L-dopa 
treatment in the observed miRNAs over-expression. 
Finally, the elaboration of a more sophisticated in silico approach generated a 
reliable and promising target prediction. 
 
Despite the preliminary character of our study, the results provide rationale to 
perform additional experiments to clarify the role of the identified miRNAs in the 
pathogenesis of PD, to clarify their role in apoptosis and insulin resistance, to add 
further evidence in L-dopa role and to further investigate miRNAs diagnostic 
potential.  
Our study do not allow the conclusion that the identified candidate miRNAs are 
ready to be used as diagnostic markers, but contributes to identify a PD specific 
miRNAs signature. Our study suggests that microRNAs, both from peripheral 
blood and plasma, can act as diagnostic biomarkers specific for Parkinson’s 
disease or they could be a challenging resource as prognostic biomarkers  
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monitoring the disease progression and the secondary side effects, which could 
appear during the drug therapy.  
 
CONCLUDING REMARKS  
The value of miRNAs as diagnostic and prognostic biomarkers and therapeutic 
targets is now widely recognized. Within 10 years more than 1500 human miRNAs 
have been discovered and show a potential utility in clinical application. The study 
of small non-coding RNAs, and in particular the class of miRNAs, has had a great 
impact and its widespread interest in the understanding of their role in gene 
regulation is becoming fundamental to understand their physiological and 
pathological role. 
The use of miRNAs as diagnostic or prognostic biomarkers for PD is not so far to 
become real. Indeed, Petillo and collaborators published a validation study, at the 
beginning of 2015, for a panel of four plasma-based circulating miRNA biomarkers 
for PD (miR-1826, miR-450b-3p, miR-505, and miR-626), as molecular biomarkers 
and qRT-PCR as potential diagnostic assay.  
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7. PERSPECTIVES 
 
The results of this study throw the basis for future analysis in order to validate the 
deregulated miRNAs as biomarkers, to clarify the involvement of L-dopa in the 
miRNAs expression and to investigate some interesting putative miRNAs target 
genes.  
 
To confirm and validate the role of the deregulated miRNAs as diagnostic 
biomarkers for PD it will be necessary enlarge the PD and drug-naïve PD patients 
group under investigation and perform additional independent expression profiling 
studies by comparing L-dopa treated PD and drug-naïve PD patients groups. 
Furthermore, it will be possible to confirm the trend of miRNA expression 
according to the gender, after a subgroup analysis stratifying the samples by 
gender.   
 
To evaluate the impact of L-dopa treatment on the levels of miRNAs expression, 
and confirm the role of deregulated miRNAs as biomarkers for monitoring the 
response to the treatment, further investigations are needed. An interesting 
approach might be the development of a longitudinal study (pharmacokinetic 
study), able to monitor and evaluate the expression levels of the miRNAs at 
different time-points before and during drug administration, and the use of in vitro 
or ex-vivo PBMCs dopaminergic models for exploring the miRNA expression 
levels at different time-points of L-dopa dosage. 
 
In order to clarify the specific role of the deregulated miRNAs in the pathology of 
PD and to confirm the proposed hypotheses on a possible link of miRNAs to 
insulin resistance and apoptosis process and PD, it is necessary to validate some 
predicted targets in cell models through a luciferase assay and by measuring 
protein levels after over-expression and/or suppression of the analyzed miRNAs. 
In this way, it will be possible to better define the role of miR-103a-3p, miR-29a-3p, 
miR-30b-5p, and miR-30a-5p in the molecular mechanism of the pathogenesis 
and progression of Parkinson’s disease. 
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Moreover, an additional interesting approach, that is developing now, could be the 
possibility to identified miRNA-mRNA interactions or the parallel expression 
analysis of miRNAs and proteins of same samples from L-dopa and/or drug-naїve 
PD patients. Indeed, miRNAs regulate protein levels and therefore the combined 
analysis of miRNAs/protein profiles might better reflect the transcriptional program 
of normal and PD cells.  
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